

CENTRAL EUROPEAN SUMMERTIME



# 10<sup>TH</sup> WORLD CONGRESS OF MELANOMA IN CONJUNCTION WITH 17<sup>TH</sup> EADO CONGRESS



**APRIL  
15-17  
2021**

(LATEST UPDATE: 05/03/2021) **FINAL PROGRAMME**

INTERACTIVE  
VIRTUAL MEETING  
**WORLDMELANOMA2021.COM**





## Table of Contents

<b>Welcome Message</b>	<b>3</b>
<b>Congress Information</b>	<b>4</b>
Committees	4
Call for Abstracts	6
General Information A–Z	7
<b>Scientific Programme</b>	<b>8</b>
Thursday, April 15	9
Friday, April 16	18
Saturday, April 17	27
<b>Sponsored Symposia</b>	<b>35</b>
<b>Sponsors</b>	<b>43</b>

### Important Deadlines

<b>March 5, 2021</b>	Deadline for abstract submission
<b>March 19, 2021</b>	Notification of acceptance of abstracts
<b>March 28, 2021</b>	Late-breaking abstract deadline
<b>April 1, 2021</b>	Notification of acceptance of late-breaking abstracts



## Welcome Message

Dear colleagues and friends,

We have the great honour and pleasure to invite you to join us for the **10<sup>th</sup> World Congress of Melanoma in conjunction with the 17<sup>th</sup> EADO Congress** which will be held under the auspices of the Melanoma World Society (MWS) and European Association of Dermato-Oncology (EADO).

The first World Congress of Melanoma took place in Venice in 1985. Since then the conference has become a well-established meeting which is held every four years. **In 2021 the event will celebrate its tenth anniversary.** Due to worldwide restrictions in connection with the COVID-19 pandemic, the congress must unfortunately take place virtually in its anniversary year.

The scientific programme will provide **rich educational opportunities for all delegates.** The field of melanoma will be covered as well as Squamous Cell Carcinoma (SCC), Merkel Cell Carcinoma (MCC), Basal Cell Carcinoma (BCC), Actinic Keratosis, Cutaneous Sarcoma and Cutaneous T- and B-Cell Lymphoma.

The congress offers a great opportunity for young doctors and researchers to familiarize themselves with melanoma and non-melanoma skin cancers. The entire spectrum of questions related to melanoma and non-melanoma skin cancers will be covered. Epidemiology, prevention and early detection, diagnostics and staging, surgical and radiotherapy and systemic and intralesional therapies are core themes of the meeting.

We are confident that the interactive virtual meeting will represent unforgettable professional and personal experience for all delegates and we look forward to welcoming you ONLINE in April 2021!

Prof. Paolo Ascierto  
Congress President

Prof. Claus Garbe  
Congress President

Prof. Axel Hauschild  
Congress President

Prof. Ketty Peris  
Congress President

Prof. Mario Santinami  
Congress President





## Congress Information

## COMMITTEES

## CALL FOR ABSTRACTS

## GENERAL INFORMATION A–Z

## COMMITTEES

### Congress Presidents

Paolo **Ascierto**, Naples, Italy  
Claus **Garbe**, Tuebingen, Germany  
Axel **Hauschild**, Kiel, Germany  
Ketty **Peris**, Rome, Italy  
Mario **Santinami**, Milan, Italy

### Abstract Committee

Corrado **Caracò**, Naples, Italy  
Michele **del Vecchio**, Milan, Italy  
Alessandro **Di Stefani**, Rome, Italy  
Giuseppe **Palmieri**, Pozzuoli, Italy  
Franco **Picciotto**, Turin Italy  
Nicola **Pimpinelli**, Florence, Italy  
Ernesto **Rossi**, Rome Italy  
Pietro **Rubegni**, Siena, Italy  
Paolo **Sena**, Bergamo, Italy  
Ignazio **Stanganelli**, Meldola, Italy

### Congress Faculty

#### A

Sanjiv **Agarwala**, Philadelphia, USA  
Joseph **Alcalay**, Tel Aviv, Israel  
Salvador Martin **Algarra**, Pamplona, Spain  
Rodabe **Amaria**, Austin, USA  
Robert **Andtbacka**, Edison, USA  
Martina **Angi**, Milan, Italy  
Andrea **Anichini**, Milan, Italy  
Zoe **Apalla**, Thessaloniki, Greece  
Ana **Arance**, Barcelona, Spain  
Guiseppe **Argenziano**, Naples, Italy  
Paolo **Ascierto**, Naples, Italy

#### B

Carlos **Barcaui**, Rio de Janeiro, Brazil  
Kathleen **Barnard**, Vancouver, Canada  
Nicole **Basset-Seguín**, Paris, France  
Lars **Bastholt**, Odense, Denmark  
Boris **Bastian**, San Francisco, USA  
Veronique **Bataille**, London, United Kingdom  
Jürgen **Becker**, Essen, Germany  
Marco **Benazzo**, Turin, Italy  
Carola **Berking**, Erlangen, Germany  
Emily **Bernstein**, New York, USA  
Christian **Blank**, Amsterdam, The Netherlands  
Anja **Bosserhoff**, Erlangen, Germany

Paolo **Bossi**, Milan, Italy  
Brigitte **Bressac-de Pailleters**, Paris, France  
Titus **Brinker**, Heidelberg, Germany  
Patrick **Brück**, Mainz, Germany  
Matilda **Bylaitė-Bučinskienė**, Vilnius, Lithuania

#### C

Cristina **Carrera**, Barcelona, Spain  
Nathalie **Cassoux**, Paris, France  
Alex **Chamberlain**, Malvern, Australia  
John Wen-Cheng **Chang**, Taoyuan, Taiwan  
Claudia **Cidonio**, Canelones, Uruguay  
Gabriela **Cinat**, Buenos Aires, Argentina  
Claudio **Conforti**, Trieste, Italy  
Pippa **Corrie**, Cambridge, United Kingdom  
Sarah E. **Coupland**, Liverpool, United Kingdom  
Chuanliang **Cui**, Peking, China

#### D

Diona **Damian**, Sydney, Australia  
Diwakar **Davar**, Pittsburgh, USA  
Michael **Davies**, Houston, USA  
Arnaud **de la Fouchardière**, Lyon, France  
Veronique **Del Marmol**, Brussels, Belgium  
Lev **Demidov**, Moscow, Russia  
Esther **de Vries**, Bogotá, Colombia  
Adi **Diab**, Houston, USA  
Anna Maria **Di Giacomo**, Siena, Italy  
Emi **Dika**, Bologna, Italy  
Brigitte **Dreno**, Nantes, France  
Reinhard **Dummer**, Zurich, Switzerland

#### E

Alexander **Eggermont**, Utrecht, The Netherlands  
Thomas **Eigentler**, Tuebingen, Germany  
Enzo **Errichetti**, Udine, Italy

#### F

Maria Concetta **Fargnoli**, L'Aquila, Italy  
Mark **Faries**, Los Angeles, USA  
Ana-Maria **Forsea**, Bucharest, Romania

#### G

Thomas **Gajewski**, Chicago, USA  
Julia **Gallinger**, Hamburg, Germany  
Claus **Garbe**, Tuebingen, Germany  
Christoffer **Gebhardt**, Hamburg, Germany  
Jeffrey **Gershenswald**, Houston, USA  
Alexandra **Geusau**, Vienna, Austria  
Helen **Gogas**, Athens, Greece

Stephan **Grabbe**, Mainz, Germany  
 Klaus **Griewank**, Mainz, Germany  
 Jean Jacques **Grob**, Marseille, France  
 Neil D. **Gross**, Houston, USA  
 Dirk **Grünhagen**, Rotterdam, The Netherlands  
 Samantha **Guild**, Richmond, USA  
 Jun **Guo**, Beijing, China  
 Ralf **Gutzmer**, Hanover, Germany

## H

John **Haanen**, Amsterdam, The Netherlands  
 Waqar **Hague**, Houston, USA  
 Allan C. **Halpern**, New York, USA  
 Omid **Hamid**, Los Angeles, USA  
 Holger **Hänßle**, Heidelberg, Germany  
 Catherine **Harwood**, London, United Kingdom  
 Jessica **Hassel**, Heidelberg, Germany  
 Axel **Hauschild**, Kiel, Germany  
 Nicholas **Hayward**, Brisbane, Australia  
 Lucie **Heinzerling**, Munich, Germany  
 Tina **Hieken**, Rochester, USA  
 Christoph **Höller**, Vienna, Austria

## I

Taiki **Isei**, Osaka, Japan

## J

Anokhi **Jambusaria Pahlajani**, Austin, USA  
 Monika **Janda**, Queensland, Australia  
 Thomas **Jouary**, Bordeaux, France

## K

Katharina **Kähler**, Kiel, Germany  
 Lidija **Kandolf-Sekulovic**, Belgrade, Serbia  
 Alexander **Katalinic**, Luebeck, Germany  
 Roland **Kaufmann**, Frankfurt, Germany  
 Nicole **Kelleners-Smeets**, Maastricht, The Netherlands  
 Harald **Kittler**, Vienna, Austria  
 Victor H. **Kölzer**, Zurich, Switzerland  
 Attila **Kovács**, Bonn, Germany  
 Art **Krieg**, Cambridge, USA

## L

Aimilios **Lallas**, Thessaloniki, Greece  
 Maria Teresa **Landi**, Bethesda, USA  
 Céleste **Lebbé**, Paris, France  
 Ulrike **Leiter**, Tuebingen, Germany  
 Mitch **Levesques**, Zurich, Switzerland  
 Elisabeth **Livingstone**, Essen, Germany  
 Georgina **Long**, Sydney, Australia  
 Caterina **Longo**, Reggio Emilia, Italy  
 Paul **Lorigan**, Manchester, United Kingdom

## M

Marcus **Maia**, São Paulo, Brazil  
 Michele **Maio**, Siena, Italy  
 Josep **Malveyh**, Barcelona, Spain  
 Mario **Mandalá**, Bergamo, Italy  
 Richard **Marais**, Manchester, United Kingdom  
 Michael **Marchetti**, New York, USA  
 Ashfaq **Marghoob**, New York, USA  
 Jean-Christophe **Marine**, Ku-Leuven, Belgium  
 Daniela **Massi**, Florence, Italy  
 Grant **McArthur**, Melbourne, Australia  
 Martin **McMahon**, Salt Lake City, USA  
 Friedegund **Meier**, Dresden, Germany  
 Ignacio **Melero**, Pamplona, Spain  
 Alexander **Menzies**, Sydney, Australia  
 Alexander **Meves**, Rochester, USA  
 Olivier **Michielin**, Lausanne, Switzerland  
 Mark **Middleton**, Oxford, United Kingdom  
 Michael **Migden**, Houston, USA  
 Zeljko **Mijuskovic**, Belgrade, Serbia  
 Peter **Mohr**, Buxtehude, Germany  
 David **Moreno-Ramirez**, Seville, Spain  
 Rodrigo R. **Munhoz**, São Paulo, Brazil

## N

Eduardo **Nagore**, València, Spain  
 Yasuhiro **Nakamura**, Hidaka, Japan  
 Paul **Nathan**, London, United Kingdom  
 Bart **Neyns**, Brussels, Belgium  
 Paul **Nghiem**, Seattle, USA  
 Van Anh **Nguyen**, Innsbruck, Austria  
 Jan P. **Nicolay**, Mannheim, Germany  
 Gillian **Nuttall**, Manchester, United Kingdom

## O

Judit **Oláh**, Szeged, Hungary  
 Friedrich **Overkamp**, Berlin, Germany

## P

John **Paoli**, Gothenburg, Sweden  
 Giovanni **Pellacani**, Rome, Italy  
 Cristina **Pellegrini**, L'Aquila, Italy  
 Ketty **Peris**, Rome, Italy  
 Teresa **Petrella**, Toronto, Canada  
 Michael **Postow**, New York, USA  
 Antonia **Pritchard**, Inverness, Scotland  
 Charlotte **Proby**, Dundee, USA  
 Susana **Puig**, Barcelona, Spain  
 Chiara **Puri Purini**, Rome, Italy

## Q

Pietro **Quaglini**, Turin, Italy  
 Paola **Queirolo**, Milan, Italy

## R

Alexander **Radbruch**, Bonn, Germany  
 Egle **Ramelyte**, Zurich, Switzerland  
 Bernado **Rapoport**, Johannesburg, South Africa  
 Simone **Ribero**, Turin, Italy  
 Erika **Richtig**, Graz, Austria  
 Jason **Rivers**, Vancouver, Canada  
 Helen **Rizos**, Sydney, Australia  
 Caroline **Robert**, Paris, France  
 Merrick **Ross**, Houston, USA  
 Piotr **Rutkowski**, Warsaw, Poland

## S

Philippe **Saiag**, Boulogne Billancourt, France  
 Mahtab **Samimi**, Tours, France  
 Mario **Santinami**, Milan, Italy  
 Julia **Scarisbrick**, Birmingham, United Kingdom  
 Jakob **Schachter**, Tel Aviv, Israel  
 Dirk **Schadendorf**, Essen, Germany  
 Bastian **Schilling**, Wuerzburg, Germany  
 Chrysalyne **Schmults**, Boston, USA  
 Erwin **Schultz**, Nuremberg, Germany  
 Richard **Scolyer**, Sydney, Australia  
 Alon **Scope**, Tel Aviv, Israel  
 Teofila Caplanusi **Seremet**, Lausanne, Switzerland  
 Ann Willman **Silk**, Boston, USA  
 Marisol **Soengas**, Madrid, Spain  
 Vernon **Sondak**, Tampa, USA  
 Hans Peter **Soyer**, Brisbane, Australia  
 Stefani **Spranger**, Cambridge, USA  
 Gilliosa **Spurrier**, Teilhet, France  
 Andreas **Stang**, Essen, Germany  
 Eggert **Stockfleth**, Bochum, Germany  
 Alexander **Stratigos**, Athens, Greece  
 Ryan J. **Sullivan**, Massachusetts, USA  
 Inge Marie **Svane**, Copenhagen, Denmark  
 Rolf-Markus **Szeimies**, Recklinghausen, Germany

## T

Alpaslan **Tasdogan**, Dallas, USA  
 Hussein **Tawbi**, Houston, USA  
 Alessandro **Testori**, Milan, Italy  
 Luc **Thomas**, Lyon, France  
 Daniela **Thommen**, Amsterdam, The Netherlands  
 Aaron **Thrift**, Houston, USA  
 Philipp **Tschandl**, Vienna, Austria  
 Samra **Turajlic**, London, United Kingdom  
 Christopher G. **Twitty**, Pennington, USA

## U

Selma **Ugurel**, Essen, Germany  
 Viktor **Umansky**, Heidelberg, Germany  
 Jochen **Utikal**, Mannheim, Germany

## V

Alexander **van Akkooi**, Amsterdam The Netherlands  
 Renata **Varaljai**, Essen, Germany  
 Martin **Vermeer**, Leiden, The Netherlands  
 Ricardo **Vieira**, Coimbra, Portugal  
 Amaya **Viros**, Manchester, United Kingdom

## W

Alberto **Wainstein**, Belo Horizonte, Brazil  
 Jennifer **Wargo**, Houston, USA  
 Jeffrey **Weber**, New York, USA  
 Ashani **Weeraratna**, Baltimore, USA  
 Michael **Weichenthal**, Kiel, Germany  
 Matthew **Wheater**, Southampton, United Kingdom  
 Dagmar **Whitaker**, Cape Town, South Africa  
 David **Whiteman**, Brisbane, Australia  
 James **Wilmott**, Sydney, Australia  
 Anna K. **Winge-Main**, Oslo, Norway  
 Jedd **Wolchok**, New York, USA  
 Michel **Wouters**, Amsterdam, The Netherlands

## Y

Iwei **Yeh**, San Francisco, USA

## Z

Iris **Zalaudek**, Trieste, Italy

# CALL FOR ABSTRACTS

## Abstract Submission Deadline: March 5, 2021

All those interested in presenting abstracts at the 10<sup>th</sup> World Congress of Melanoma and 17<sup>th</sup> EADO Congress are invited to submit their work to the Programme Committee for review.

Notification of Acceptance of Abstracts: March 19, 2021

## Abstract Topics

- › Actinic keratoses
- › Basal cell carcinoma
- › Cutaneous sarcoma
- › Cutaneous T- and B-cell lymphoma
- › Melanoma
- › Merkel cell carcinoma
- › Rare tumors
- › Squamous cell carcinoma

## Abstract Guidelines

- › Abstracts may be submitted online at <https://worldmelanoma2021.com/call-for-abstracts/abstract-submission/>. Abstracts submitted by fax or e-mail will not be accepted.
- › Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.
- › Please indicate the topic from the abstract topics list. Abstracts will be designated for e-poster presentations. Encore abstracts will be accepted.
- › Please structure the abstract as follows: Background, Methods, Results, Conclusions. The text shall not exceed 4000 characters including spaces.
- › It is acceptable to include up to two tables or graphics as part of the abstract.
- › All abstracts must be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. Abstracts will not be edited by the Congress Secretariat prior to publication, therefore please check the grammar and spelling carefully.
- › We kindly ask authors to not use any commercial names of medications or drugs, but rather to use generic names instead.

## E-Poster Presentation

Abstracts selected for poster will be presented as e-Posters during the virtual conference. For further information please visit the congress website

## Poster Awards

The best three virtual posters on display will be awarded during the virtual congress with an award of 500 Euro each. The poster prize will be awarded on Saturday, April 17 from 17:15–17:25.

The awards are kindly supported by several companies (see page 42).

## Late Breaking Abstracts

We are pleased to announce that the online submission of late-breaking abstracts will be possible from March 22–28, 2021. For further information please visit the congress website.

## Registration

Please note that the acceptance of an abstract does not include the congress registration. The presenting author must be a registered participant, otherwise the abstract will not be reviewed and waived from the programme.



# GENERAL INFORMATION A–Z

## Cancellation Policy

Cancellations must be received in writing by February 14, 2021. No refunds will be granted after that date. A processing fee of 30 Euro will be deducted from each cancelled registration. Substitutions are possible. To substitute a registration, please send an email including the name of the original registrant and the name of the person substituting to: [registration@worldmelanoma2021.com](mailto:registration@worldmelanoma2021.com).

## CME Certificate / Certificate of Attendance

An application for CME accreditation will be made. For receiving CME credits, an online evaluation form needs to be filled out. You can download your personalized CME certificate on each congress day from 16:00 CEST at the CME booth in the industrial exhibition. It is also possible to download certificates for past congress days provided that you were logged in to the platform on those days. The attendance in the virtual environment will be captured. The online evaluation only needs to be completed once. It is not necessary to enter the name. The system automatically adopts the name entered during online registration.

A download of the certificates is possible until the closing of the platform on Sunday, 18.04.2021 at 23:59 CEST.

## Congress Organization

### MedConcept

Gesellschaft für medizinische Projekte mbH  
Friedenstr. 58  
15366 Neuenhagen bei Berlin  
Germany

Phone +49 (0)3342 4268930  
Fax +49 (0)3342 4268940

Responsible Project Manager: Mrs. Mirja Christ  
Email: [congress@worldmelanoma2021.com](mailto:congress@worldmelanoma2021.com)  
[www.medconcept.org](http://www.medconcept.org)

## Language and Translation

The official language of the meeting is English. Simultaneous translation will not be provided.

## Liability Disclaimer

In the unlikely occurrence that the congress must be cancelled or postponed due to circumstances beyond the control of the organizers (natural disasters, political, social or economic events or other unforeseen events beyond control), the organizers cannot be held liable for any costs incurred by the event attendee. The organizers will record images during the event. By virtue of attendance, attendees agree to the organizers usage of these recordings on the website and for marketing.

## Programme Changes

The organizer reserves the right to make changes to the event programme at short notice if necessary. This does not result in any reimbursement claims. Programme changes will be announced during the congress.

## Registration

Registration is only possible by using the online portal on the congress website: <https://worldmelanoma2021.com/registration/individual-registration/>.

Group registrations are possible from 5 persons and can also only be booked online.

Registration Type	Registration Fee
Full Delegates	200 €
Students / Residents / Nurse*	100 €

\* The student/residents/nurse registration rate will be granted only after receipt of proof of ID.  
The proof of ID can be uploaded online during the registration process.

## Registration fee covers:

- Admission to online scientific sessions and satellite symposia
- Admission to the virtual industrial exhibition
- Certificate of attendance
- Book of abstracts

## Method of payment:

Only credit cards (Visa, MasterCard, American Express) will be accepted. Bank transfers are only possible in exceptional cases for group bookings/hospitals. Please note that in payments by bank transfers, the bank charges must be paid by the delegate.

## Time Zone

Please note that all live sessions and live Q&A's during the virtual congress will take place according to Central European Summer Time CEST/GMT+2.

## Virtual Industrial Exhibition

A virtual industrial exhibition will be available in the online congress portal.





## Scientific Programme

THURSDAY, APRIL 15

FRIDAY, APRIL 16

SATURDAY, APRIL 17



	LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C	
07:00						08:00
08:00	07:45–08:00 Opening Ceremony					08:00
	08:00–09:15 Symposium SY01 Epidemiologic trends in melanoma	08:00–09:15 Symposium SY02 Squamous cell carcinoma: epidemiology and management	08:00–09:15 Symposium SY03 Merkel cell carcinoma: epidemiology, surgery and radiology	08:00–09:00 Symposium SY04 Dermoscopy 1: total body photography, digital dermatoscopy and scanners: indications and procedures	08:00–09:15 Symposium SY05 Patient Advocates	
09:00						09:00
	09:30–10:45 Symposium SY06 Controversies in dermato-oncology	09:30–10:30 Satellite Symposium SAT01 Gold Sponsor (see page 35)	09:30–10:30 Symposium SY07 Liquid biopsy	09:30–10:45 Symposium SY08 Intralesional therapies of skin cancer	09:30–10:30 Symposium SY09 Prognostic and predictive biomarkers in melanoma	
10:00						10:00
	11:00–12:30 Keynote Lecture KEY01 Systemic versus intralesional immunotherapy – different biology?					11:00
12:00						12:00
	12:45–13:45 Satellite Symposium SAT02 Platinum Sponsor (see page 35)					13:00
13:00						
	14:00–15:00 Symposium SY10 Advances in melanoma staging and prognosis: AJCC V8, integrative risk modeling, and beyond	14:00–15:00 Satellite Symposium SAT03 Gold Sponsor (see page 36)	14:00–15:00 Symposium SY11 Epigenetic modulation in skin cancer	14:00–15:00 Symposium SY12 Adoptive T-cell transfer	14:00–15:00 Symposium SY13 Cutaneous lymphomas: what is new?	14:00
15:00						15:00
	15:15–16:15 Symposium SY14 Neoadjuvant treatment of melanoma	15:15–16:15 Symposium SY15 Immunotherapy of merkel cell carcinoma	15:15–16:15 Satellite Symposium SAT04 Further Sponsor (see page 36)	15:15–16:15 Symposium SY16 Basal cell carcinoma: epidemiology and management	15:15–16:15 Symposium SY17 Ocular melanoma: similar and yet so different from other melanomas	16:00
16:00						
		16:30–17:30 Symposium SY18 Drug resistance to immune checkpoint inhibition	16:30–17:30 Satellite Symposium SAT05 Further Sponsor (see page 37)	16:30–17:30 Symposium SY19 Artificial intelligence in medical oncology, pathology and radiology	16:30–17:30 Symposium SY19A Skin Care in Organ Transplant Patients Europe (SCOPE)	17:00
17:00						
		17:45–18:45 Satellite Symposium SAT05A Bronze Sponsor (see page 37)	17:45–19:15 Symposium SY19B Registries for real world treatment data and outcome research	17:45–18:45 Symposium SY19C Drug resistance to targeted therapies		18:00
18:00						
						19:00
19:00						



THURSDAY, APRIL 15

THURSDAY, APRIL 15

SCIENTIFIC PROGRAMME

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
07:45–8:00				
<div>Opening Ceremony</div> <div>Paolo Ascierto, Naples, Italy</div> <div>Claus Garbe, Tuebingen, Germany</div> <div>Axel Hauschild, Kiel, Germany</div> <div>Ketty Peris, Rome, Italy</div> <div>Mario Santinami, Milan, Italy</div>				



THURSDAY, APRIL 15

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
08:00–9:15	08:00–9:15	08:00–9:15	08:00–9:00	08:00–9:15
<b>Symposium SY01</b> <b>Epidemiologic trends in melanoma</b>	<b>Symposium SY02</b> <b>Squamous cell carcinoma: epidemiology and management</b>	<b>Symposium SY03</b> <b>Merkel cell carcinoma: epidemiology, surgery and radiology</b>	<b>Symposium SY04</b> <b>Dermoscopy 1: total body photography, digital dermatoscopy and scanners: indications and procedures</b>	<b>Symposium SY05</b> <b>Patient Advocates</b>
<b>08:00–08:03</b> <b>Introduction</b> David Whiteman, Brisbane, Australia	<b>08:00–08:03</b> <b>Introduction</b> Alexander Stratigos, Athens, Greece	<b>08:00–08:03</b> <b>Introduction</b> Roland Kaufmann, Frankfurt, Germany	<b>08:00–08:03</b> <b>Introduction</b> Marcus Maia, São Paulo, Brazil	<b>08:00–08:03</b> <b>Introduction</b> Samantha Guild, Richmond, USA
<b>08:03–08:15</b> <b>Melanoma trends in Australia and Asia</b> David Whiteman, Brisbane, Australia	<b>08:03–08:15</b> <b>Epidemiology and prognostic classification</b> Alexander Stratigos, Athens, Greece	<b>08:03–08:18</b> <b>Epidemiology of primary MCC</b> Andreas Stang, Essen, Germany	<b>08:03–08:18</b> <b>Cost–efficiency evaluation of digital dermoscopy</b> Marcus Maia, São Paulo, Brazil	<b>08:03–08:18</b> <b>The power of the collaboration between patients and advocates</b> Chiara Puri Purini, Rome, Italy
<b>08:15–08:27</b> <b>Melanoma trends in Africa</b> Dagmar Whitaker, Cape Town, South Africa	<b>08:15–08:27</b> <b>Surgical approaches to common and high risk cSCC</b> Ricardo Vieira, Coimbra, Portugal	<b>08:18–08:33</b> <b>MCC in immunosuppressed patient</b> Céleste Lebbé, Paris, France	<b>08:18–08:33</b> <b>Strategies using digital dermoscopy and total body photography</b> Luc Thomas, Lyon, France	<b>08:18–08:33</b> <b>Information is the first step to the cure</b> Claudia Cidonio, Canelones, Uruguay
<b>08:27–08:39</b> <b>Melanoma trends in North America</b> Aaron Thrift, Houston, USA	<b>08:27–08:39</b> <b>Current medical management of advanced cSCC</b> Michael Migden, Houston, USA	<b>08:33–08:48</b> <b>Best surgical modalities for the management of stage I to III MCC</b> Roland Kaufmann, Frankfurt, Germany	<b>08:33–08:48</b> <b>Past, present, and future of artificial intelligence in dermoscopy</b> Holger Hännle, Heidelberg, Germany	<b>08:33–08:48</b> <b>Advocacy: from diagnosis to survivorship and beyond</b> Kathleen Barnard, Vancouver, Canada
<b>08:39–08:51</b> <b>Melanoma trends in South America</b> Esther de Vries, Bogotá, Colombia	<b>08:39–08:51</b> <b>Ongoing and new approaches in high risk cSCC</b> Chrysalyne Schmults, Boston, USA	<b>08:48–09:03</b> <b>Impact/role of radiotherapy in management of MCC</b> Paul Nghiem, Seattle, USA	<b>08:48–09:00</b> <b>Summary</b> Luc Thomas, Lyon, France	<b>08:48–09:03</b> <b>Melanoma U.K.: improving patient outcomes through collaboration</b> Gillian Nuttall, Manchester, United Kingdom
<b>09:03–09:15</b> <b>Discussion</b> Alexander Katalinic, Luebeck, Germany David Whiteman, Brisbane, Australia	<b>09:03–09:15</b> <b>Discussion</b> Paola Queirolo, Milan, Italy Alexander Stratigos, Athens, Greece	<b>09:03–09:15</b> <b>Summary</b> Celeste Lebbé, Paris, France		<b>09:03–09:15</b> <b>Summary</b> Gilliosa Spurrier, Teilhet, France
<b>09:15–09:30</b> Break – Please visit the virtual industrial exhibition and e-poster exhibition.				



THURSDAY, APRIL 15

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
09:30–10:45	09:30–10:30	09:30–10:30	09:30–10:45	09:30–10:30
<b>Symposium SY06</b> <b>Controversies in dermato-oncology</b>	<b>Satellite Symposium SAT01</b> <b>Gold Sponsor</b> <i>(see page 35)</i>	<b>Symposium SY07</b> <b>Liquid biopsy</b>	<b>Symposium SY08</b> <b>Intralesional therapies of skin cancer</b>	<b>Symposium SY09</b> <b>Prognostic and predictive biomarkers in melanoma</b>
<b>09:30–09:32</b> <b>Introduction</b> Catherine Harwood, London, United Kingdom		<b>09:30–09:33</b> <b>Introduction</b> Andreas Stang, Essen, Germany	<b>09:30–09:33</b> <b>Introduction</b> Mark Middleton, Oxford, United Kingdom	<b>09:30–09:33</b> <b>Introduction</b> Selma Ugurel, Essen, Germany
<b>Skin cancer screening saves lives!?</b>		<b>09:33–09:48</b> <b>ctDNA analysis and applications in oncology</b> Helen Rizos, Sydney, Australia	<b>09:33–09:48</b> <b>Established treatments – the lessons from history</b> Chrysalyne Schmults, Boston, USA	<b>09:33–09:48</b> <b>Role of MDSCs as prognostic and predictive biomarkers in melanoma</b> Viktor Umansky, Heidelberg, Germany
<b>09:32–09:44</b> <b>Yes:</b> Peter Mohr, Buxtehude, Germany				
<b>09:44–09:56</b> <b>No:</b> Ana-Maria Forsea, Bucharest, Romania		<b>09:48–10:03</b> <b>Genomic profiling of ctDNA for therapy monitoring and prognostic stratification in melanoma</b> Renata Varaljai, Essen, Germany	<b>09:48–10:03</b> <b>T-VEC: the pathfinder</b> Christoph Höller, Vienna, Austria	<b>09:48–10:03</b> <b>Primary tumor-based gene expression profile (GEP) tests in melanoma: ready for clinical use as a prognostic biomarker?</b> Michael Marchetti, New York, USA
<b>09:56–10:08 Discussion</b> Catherine Harwood, London, United Kingdom Giovanni Pellacani, Rome, Italy		<b>10:03–10:18</b> <b>Circulating tumor DNA for melanoma patients in clinical practice</b> Teofila Caplanusi Seremet, Lausanne, Switzerland	<b>10:03–10:18</b> <b>Moving beyond T-VEC – novel virotherapies</b> Mark Middleton, Oxford, United Kingdom	<b>10:03–10:18</b> <b>PD-L1 as predictive marker of immunotherapy</b> Selma Ugurel, Essen, Germany
<b>10:08–10:10</b> <b>Introduction</b> Giovanni Pellacani, Rome, Italy		<b>10:18–10:30</b> <b>Summary</b> Bart Neyns, Brussels, Belgium	<b>10:18–10:33</b> <b>Future targets for intralesional therapy</b> Ann Willman Silk, Boston, USA	<b>10:18–10:30</b> <b>Summary</b> Jochen Utikal, Mannheim, Germany
<b>Sunscreens prevent skin cancer!?</b>				
<b>10:10–10:22</b> <b>Yes:</b> Veronique Del Marmol, Brussels, Belgium				
<b>10:22–10:34</b> <b>No:</b> Claus Garbe, Tuebingen, Germany				
<b>10:34–10:45 Discussion</b> Catherine Harwood, London, United Kingdom Giovanni Pellacani, Rome, Italy			<b>10:33–10:45</b> <b>Summary</b> Chrysalyne Schmults, Boston, USA	
10:45–11:00 Break – Please visit the virtual industrial exhibition and e-poster exhibition.				



THURSDAY, APRIL 15

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
11:00–12:30				
Keynote Lecture KEY01 Systemic versus intralesional immunotherapy – different biology?				
11:00–11:01 Introduction Pippa Corrie, Cambridge, United Kingdom				
11:01–11:30 How immune cells kill tumor cells Thomas Gajewski, Chicago, USA				
11:30–11:31 Introduction Lev Demidov, Moscow, Russia				
11:31–12:00 Past, presence and future of intralesional drugs for skin cancer Jedd Wolchok, New York, USA				
12:00–12:01 Introduction Rodrigo R. Munhoz, São Paulo, Brazil				
12:01–12:30 Microbiome transplantations versus diet Jennifer Wargo, Houston, USA				
12:30–12:45 Break – Please visit the virtual industrial exhibition and e-poster exhibition.				



THURSDAY, APRIL 15

THURSDAY, APRIL 15

SCIENTIFIC PROGRAMME

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
<div>12:45–13:45</div> <div>Satellite Symposium SAT02</div> <div>Platinum Sponsor</div> <div>(see page 35)</div> <div></div>				
<div>13:45–14:00 Break – Please visit the virtual industrial exhibition and e-poster exhibition.</div>				



THURSDAY, APRIL 15

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
14:00–15:00	14:00–15:00	14:00–15:00	14:00–15:00	14:00–15:00
<b>Symposium SY10</b> <b>Advances in melanoma staging and prognosis: AJCC V8, integrative risk modeling, and beyond</b>	<b>Satellite Symposium SAT03</b> <b>Gold Sponsor</b> <i>(see page 36)</i>	<b>Symposium SY11</b> <b>Epigenetic modulation in skin cancer</b>	<b>Symposium SY12</b> <b>T-cell directed therapies in oncology</b>	<b>Symposium SY13</b> <b>Cutaneous lymphomas: what is new?</b>
<b>14:00–14:03</b> <b>Introduction</b> Jeffrey Gershenwald, Houston, USA		<b>14:00–14:03</b> <b>Introduction</b> Michele Maio, Siena, Italy	<b>14:00–14:03</b> <b>Introduction</b> Inge Marie Svane, Copenhagen, Denmark	<b>14:00–14:03</b> <b>Introduction</b> Reinhard Dummer, Zurich, Switzerland
<b>14:03–14:18</b> <b>Beyond TNM: framework for “next-gen” AJCC initiatives</b> Jeffrey Gershenwald, Houston, USA		<b>14:03–14:18</b> <b>Rationale underlying epigenetic immuno-modulation of melanoma</b> Andrea Anichini, Milan, Italy	<b>14:03–14:18</b> <b>T-cell targeting IDO/PDL1 vaccine</b> Inge Marie Svane, Copenhagen, Denmark	<b>14:03–14:18</b> <b>What is new in immunobiology and genomics in cutaneous lymphoma?</b> Martin Vermeer, Leiden, The Netherlands
<b>14:18–14:33</b> <b>Sentinel node tumor burden (and more) in stage III melanoma: lessons learned and opportunities</b> Alexander van Akkooi, Amsterdam, The Netherlands		<b>14:18–14:33</b> <b>Epigenetic immuno-modulation in the melanoma clinic</b> Anna Maria Di Giacomo, Siena, Italy	<b>14:18–14:33</b> <b>Adoptive T-cell therapy – obstacles and opportunities</b> Jakob Schachter, Tel Aviv, Israel	<b>14:18–14:33</b> <b>What is new in cutaneous B-cell lymphoma: from diagnostic to treatment?</b> Egle Ramelyte, Zurich, Switzerland
<b>14:33–14:48</b> <b>Integrative risk modeling to predict sentinel node positivity – do gene expression profiles do it best?</b> Richard Scolyer, Sydney, Australia		<b>14:33–14:48</b> <b>Epigenetic modulation in melanoma</b> Emily Bernstein, New York, USA	<b>14:33–14:48</b> <b>T-cell therapy 2.0 – what can be achieved by genetic modifications?</b> John Haanen, Amsterdam, The Netherlands	<b>14:33–14:48</b> <b>What is new in cutaneous T-cell lymphoma: from diagnostic to treatment?</b> Julia Scarisbrick, Birmingham, United Kingdom
<b>14:48–15:00</b> <b>Discussion</b> Jeffrey Gershenwald, Houston, USA Michael Weichenthal, Kiel, Germany		<b>14:48–15:00</b> <b>Summary</b> Mitch Levesques, Zurich, Switzerland	<b>14:48–15:00</b> <b>Summary</b> Jakob Schachter, Tel Aviv, Israel	<b>14:48–15:00</b> <b>Summary</b> Pietro Quaglino, Turin, Italy
<b>15:00–15:15</b> Break – Please visit the virtual industrial exhibition and e-poster exhibition.				



THURSDAY, APRIL 15

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
15:15–16:15	15:15–16:15	15:15–16:15	15:15–16:15	15:15–16:15
<b>Symposium SY14</b> <b>Neoadjuvant treatment of melanoma</b>	<b>Symposium SY15</b> <b>Immunotherapy of merkel cell carcinoma</b>	<b>Satellite Symposium SAT04</b> <b>Further Sponsor</b> <i>(see page 36)</i>	<b>Symposium SY16</b> <b>Basal cell carcinoma: epidemiology and management</b>	<b>Symposium SY17</b> <b>Ocular melanoma: similar and yet so different from other melanomas</b>
<b>15:15–15:18</b> <b>Introduction</b> Christian Blank, Amsterdam, The Netherlands	<b>15:15–15:18</b> <b>Introduction</b> Jürgen Becker, Essen, Germany		<b>15:15–15:18</b> <b>Introduction</b> Matilda Bylaitė-Bučinskienė, Vilnius, Lithuania	<b>15:15–15:18</b> <b>Introduction</b> Martina Angi, Milan, Italy
<b>15:18–15:33</b> <b>Neoadjuvant checkpoint inhibitor combinations</b> Christian Blank, Amsterdam, The Netherlands	<b>15:18–15:33</b> <b>PD(L)-1 in MCC and options for addressing resistance with current tools</b> Jürgen Becker, Essen, Germany		<b>15:18–15:33</b> <b>Epidemiology and clinical-morphological correlation</b> Matilda Bylaitė-Bučinskienė, Vilnius, Lithuania	<b>15:18–15:33</b> <b>Diagnosis and treatment of uveal melanoma</b> Nathalie Cassoux, Paris, France
<b>15:33–15:48</b> <b>Neoadjuvant combinations with targeted therapies</b> Rodabe Amaria, Austin, USA	<b>15:33–15:48</b> <b>Adjuvant, neo-adjuvant and ‘up-front’ immunotherapy for loco-regionally advanced MCC</b> Mahtab Samimi, Tours, France		<b>15:33–15:48</b> <b>Surgical procedures</b> Roland Kaufmann, Frankfurt, Germany	<b>15:33–15:48</b> <b>Diagnosis and treatment of conjunctival melanoma</b> Martina Angi, Milan, Italy
<b>15:48–16:03</b> <b>Neoadjuvant combinations with innate immunity stimulation</b> Diwakar Davar, Pittsburgh, USA	<b>15:48–16:03</b> <b>Promising approaches and trials for advanced MCC</b> Paul Nghiem, Seattle, USA		<b>15:48–16:03</b> <b>Medical treatments</b> Ketty Peris, Rome, Italy	<b>15:48–16:03</b> <b>Pathology and therapeutic implications of ocular melanoma</b> Sarah E. Coupland, Liverpool, United Kingdom
<b>16:03–16:15</b> <b>Discussion</b> Christian Blank, Amsterdam, The Netherlands Paolo Ascierto, Naples, Italy	<b>16:03–16:15</b> <b>Discussion</b> Jürgen Becker, Essen, Germany Paul Nghiem, Seattle, USA		<b>16:03–16:15</b> <b>Summary</b> Ketty Peris, Rome, Italy	<b>16:03–16:15</b> <b>Summary</b> Nathalie Cassoux, Paris, France
<b>16:15–16:30</b> Break – Please visit the virtual industrial exhibition and e-poster exhibition.				

THURSDAY, APRIL 15

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
	16:30–17:30	16:30–17:30	16:30–17:30	16:30–17:30
	Symposium SY18 Drug resistance to immune checkpoint inhibition	Satellite Symposium SAT05 Further Sponsor (see page 37)	Symposium SY19 Artificial intelligence in medical oncology, pathology and radiology	Symposium SY19A Skin Care in Organ Transplant Patients Europe (SCOPE)
	16:30–16:33 Introduction Marisol Soengas, Madrid, Spain		16:30–16:33 Introduction Friedrich Overkamp, Berlin, Germany	16:30–16:33 Introduction Alexandra Geusau, Vienna, Austria
	16:33–16:48 Predictors of response and resistance of PD1 checkpoint blockade Bastian Schilling, Wuerzburg, Germany		16:33–16:42 Digitalization in oncology: current applications and future directions Friedrich Overkamp, Berlin, Germany	16:33–16:48 Practical applications for immunotherapy in an immunosuppressed patient Chrysalyne Schmults, Boston, USA
	16:48–17:03 Metabolic heterogeneity confers differences in melanoma metastatic potential Alpaslan Tasdogan, Dallas, USA		16:42–16:51 Artificial intelligence in the interpretation of imaging examinations Alexander Radbruch, Bonn, Germany	16:48–16:58 Donor cancer transmission Catherine Harwood, London, United Kingdom
	17:03–17:18 Imaging and targeting (pre)metastatic niches in melanoma Marisol Soengas, Madrid, Spain		16:51–17:00 Implementation of digital pathology into diagnostic practice Titus Brinker, Heidelberg, Germany	16:58–17:08 Consensus based recommendations for the prevention of skin cancer in solid organ transplant recipients: results of an international delphi study Anokhi Jambusaria Pahlajani, Austin, USA
	17:18–17:30 Discussion Dirk Schadendorf, Essen, Germany Marisol Soengas, Madrid, Spain		17:00–17:09 Precision immunoprofiling by image analysis and artificial intelligence Victor H. Koelzer, Zurich, Switzerland	17:08–17:18 Tumor or infection Alexandra Geusau, Vienna, Austria
			17:09–17:18 Artificial intelligence in oncology Olivier Michielin, Lausanne, Switzerland	17:18–17:30 Summary Charlotte Proby, Dundee, USA
			17:18–17:30 Summary Olivier Michielin, Lausanne, Switzerland	
17:30–17:45 Break – Please visit the virtual industrial exhibition and e-poster exhibition.				



THURSDAY, APRIL 15

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
	17:45–18:45	17:45–19:15	17:45–18:45	
	Satellite Symposium SAT05A Bronze Sponsor (see page 37)	Symposium SY19B Registries for real world treatment data and outcome research	Symposium SY19C Drug resistance to targeted therapies	
		17:45–17:48 Introduction Susana Puig, Barcelona, Spain	17:45–17:48 Introduction Carola Berking, Erlangen, Germany	
		17:48–18:03 Are real world data suitable for outcome research in melanoma and non-melanoma skin cancer? Céleste Lebbé, Paris, France	17:48–18:03 Melanoma persister cells: the invisible threat Caroline Robert, Paris, France	
		18:03–18:18 Real-world outcomes of advanced melanoma patients not represented in phase III trials Michel Wouters, Amsterdam, The Netherlands	18:03–18:18 Evolutionary predictability of genetic versus nongenetic resistance to targeted therapy Jean-Christophe Marine, Leuven, Belgium	
		18:18–18:33 Real world data on non-melanoma skin cancer: insights from the German Merkel Cell Carcinoma Registry Selma Ugurel, Essen, Germany	18:18–18:33 Can immunotherapy overcome resistance to BRAF-inhibition in melanoma Grant McArthur, Melbourne, Australia	
		18:33–18:48 DAMMED: Real world outcome data in metastatic melanoma – results from Denmark (2011–2020) included in the EUMelaReg collaboration Lars Bastholt, Odense, Denmark	18:33–18:45 Summary Amaya Viros, Manchester, United Kingdom	
		18:48–19:03 Disparities in the delivery of immunotherapy for metastatic melanoma in the United States: results from The National Cancer Database Waqar Hague, Houston, USA		
		19:03–19:15 Summary Michael Weichenthal, Kiel, Germany		

## Scientific Programme

FRIDAY, APRIL 16

SCIENTIFIC PROGRAMME

	LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C	
08:00	08:00–09:00 <b>Symposium SY20</b> Controversies in radiotherapy	08:00–09:00 <b>Symposium SY21</b> New druggable targets in ...	08:00–09:00 <b>Satellite Symposium SAT06</b> Further Sponsor (see page 38)	08:00–09:00 <b>Symposium SY22</b> Management of mucosal melanoma	08:00–09:00 <b>Symposium SY23</b> Management of acral lentiginous melanomas	08:00
09:00						09:00
	09:15–10:15 <b>Symposium SY24</b> Controversies in melanoma management	09:15–10:15 <b>Satellite Symposium SAT07</b> Bronze Sponsor (see page 38)		09:15–10:15 <b>Symposium SY25</b> Molecular tumor board for skin cancer	09:15–10:15 <b>Symposium SY26</b> Quality assurance in dermato-oncology	
10:00						10:00
	10:30–11:30 <b>Symposium SY27</b> Adjuvant treatment of melanoma	10:30–11:30 <b>Symposium SY28</b> Sentinel node biopsy: techniques and future perspectives	10:30–11:30 <b>Satellite Symposium SAT08</b> Further Sponsor (see page 39)	10:30–11:30 <b>Symposium SY29</b> Management of metastatic ocular melanoma	10:30–11:30 <b>Symposium SY30</b> Management of brain metastasis	
11:00						11:00
	11:45–12:45 <b>Satellite Symposium SAT09</b> Platinum Sponsor (see page 39)					
12:00						12:00
	13:00–14:30 <b>Keynote Lecture KEY02</b> Fundamental questions in dermato-oncology					
13:00						13:00
	14:45–15:45 <b>Satellite Symposium SAT10</b> Platinum Sponsor (see page 40)					
14:00						14:00
15:00						15:00
	16:00–17:00 <b>Symposium SY31</b> Immune checkpoint inhibition for non-melanoma skin cancer	16:00–17:00 <b>Symposium SY32</b> Regulation of drug access across the world	16:00–17:00 <b>Satellite Symposium SAT11</b> Further Sponsor (see page 40)	16:00–17:00 <b>Symposium SY33</b> Immune checkpoint inhibition in immunocompromised patients	16:00–17:00 <b>Symposium SY34</b> New devices for skin cancer diagnostics	
16:00						16:00
	17:15–18:15 <b>Symposium SY35</b> Highlights from AACR	17:15–18:15 <b>Symposium SY36</b> Melanocytic nevi: risks and management	17:15–18:00 <b>Satellite Symposium SAT12</b> Further Sponsor (see page 41)	17:15–18:15 <b>Symposium SY37</b> Promising agents for PD1-refractory patients	17:15–18:15 <b>Symposium SY38</b> Triplets for advanced metastatic melanoma: still hope for the future?	
17:00						17:00
18:00						18:00



FRIDAY, APRIL 16

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
08:00–9:00	08:00–9:00	08:00–9:00	08:00–9:00	08:00–9:00
Symposium SY20 Controversies in radiotherapy	Symposium SY21 New druggable targets in ...	Satellite Symposium SAT06 Further Sponsor (see page 38)	Symposium SY22 Management of mucosal melanoma	Symposium SY23 Management of acral lentiginous melanomas
<div>08:00–08:01 Introduction Salvador Martin Algarra, Pamplona, Spain</div> <div>Radiotherapy elicits an abscopal effect!? 08:01–08:11 Yes: Philippe Saiag, Boulogne Billancourt, France 08:11–08:21 No: Jeffrey Weber, New York, USA 08:21–08:30 Discussion Salvador Martin Algarra, Pamplona, Spain Mario Mandala, Bergamo, Italy</div> <div>08:30–08:31 Introduction Mario Mandala, Bergamo, Italy</div> <div>Adjuvant radiotherapy should be abandoned!? 08:31–08:41 Yes: Paul Lorigan, Manchester, United Kingdom 08:41–08:51 No: Lars Bastholt, Odense, Denmark 08:51–09:00 Discussion Salvador Martin Algarra, Pamplona, Spain Mario Mandala, Bergamo, Italy</div>	<div>08:00–08:03 Introduction Elisabeth Livingstone, Essen, Germany</div> <div>08:03–08:18 ... keratinocyte skin cancer Paolo Ascierto, Naples, Italy</div> <div>08:18–08:33 ... immunotherapy Dirk Schadendorf, Essen, Germany</div> <div>08:33–08:48 ... melanoma Grant McArthur, Melbourne, Australia</div> <div>08:48–09:00 Discussion Elisabeth Livingstone, Essen, Germany Martin McMahon, Salt Lake City, USA</div>		<div>08:00–08:03 Introduction Jun Guo, Beijing, China</div> <div>08:03–08:18 ICI and combination for mucosal melanoma, palliative and beyond Chuanliang Cui, Peking, China</div> <div>08:18–08:33 The clinical impact of the gut microbiota on immune checkpoint inhibitors in Asian mucosal and non-mucosal melanoma John Wen-Cheng Chang, Taoyuan, Taiwan</div> <div>08:33–08:48 Novel Insights into molecular diagnostics in mucosal melanoma monitoring and treatment Christoffer Gebhardt, Hamburg, Germany</div> <div>08:48–09:00 Summary Christoffer Gebhardt, Hamburg, Germany</div>	<div>08:00–08:03 Introduction Taiki Isei, Osaka, Japan</div> <div>08:03–08:18 What is the difference from common types of cutaneous melanoma? Taiki Isei, Osaka, Japan</div> <div>08:18–08:33 Surgical management for ALM Yasuhiro Nakamura, Saitama, Japan</div> <div>08:33–08:48 Immuno-oncology for ALM David Moreno-Ramirez, Seville, Spain</div> <div>08:48–09:00 Summary David Moreno-Ramirez, Seville, Spain</div>
09:00–09:15 Break – Please visit the virtual industrial exhibition and e-poster exhibition.				

FRIDAY, APRIL 16

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
09:15–10:15	09:15–10:15		09:15–10:30	09:15–10:15
<b>Symposium SY24</b> <b>Controversies in melanoma management</b>	<b>Satellite Symposium SAT07</b> <b>Bronze Sponsor</b> <i>(see page 38)</i>		<b>Symposium SY25</b> <b>Molecular tumor board for skin cancer</b>	<b>Symposium SY26</b> <b>Quality assurance in dermato-oncology</b>
<b>09:15–09:16</b> <b>Introduction</b> Ana Arance, Barcelona, Spain			<b>09:15–09:18</b> <b>Introduction</b> Anja Bosserhoff, Erlangen, Germany	<b>09:15–09:18</b> <b>Introduction</b> Thomas Eigentler, Tuebingen, Germany
<b>All BRAF mutated patients should be primarily treated with BRAF/MEK inhibitors!?</b> <b>09:16–09:26</b> <b>Yes:</b> Michael Postow, New York, USA <b>09:26–09:36</b> <b>No:</b> Georgina Long, Sydney, Australia <b>09:36–09:45</b> <b>Discussion</b> Ana Arance, Barcelona, Spain Axel Hauschild, Kiel, Germany			<b>09:18–09:33</b> <b>Genomics of acral melanoma: implications for therapy</b> Boris Bastian, San Francisco, USA	<b>09:18–09:33</b> <b>Certification in dermatooncology</b> Ana-Maria Forsea, Bucharest, Romania
<b>09:45–09:46</b> <b>Introduction</b> Axel Hauschild, Kiel, Germany			<b>09:33–09:48</b> <b>How to use high resolution translational data in daily clinic</b> Reinhard Dummer, Zurich, Switzerland	<b>09:33–09:48</b> <b>Interdisciplinary skin cancer centers in Germany</b> Thomas Eigentler, Tuebingen, Germany
<b>Intense follow-up evaluations improve survival!?</b> <b>09:46–09:56</b> <b>Yes:</b> Ulrike Leiter, Tuebingen, Germany <b>09:56–10:06</b> <b>No:</b> Alexander van Akkooi, Amsterdam, The Netherlands <b>10:06–10:15</b> <b>Discussion</b> Ana Arance, Barcelona, Spain Axel Hauschild, Kiel, Germany			<b>09:48–10:03</b> <b>Learning from early processes in melanoma development: molecules implicates in breaking of senescence</b> Anja Bosserhoff, Erlangen, Germany	<b>09:48–10:03</b> <b>Quality control in digital pathology</b> Olivier Michielin, Lausanne, Switzerland
			<b>10:03–10:18</b> <b>Can serum markers guide treatment decisions?</b> Bastian Schilling, Wuerzburg, Germany	<b>10:03–10:15</b> <b>Summary</b> Ana-Maria Forsea, Bucharest, Romania
			<b>10:18–10:30</b> <b>Summary</b> Reinhard Dummer, Zurich, Switzerland	
10:15–10:30 Break – Please visit the virtual industrial exhibition and e-poster exhibition.				



FRIDAY, APRIL 16

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
10:30–11:30	10:30–11:30	10:30–11:30	10:30–11:30	10:30–11:30
<b>Symposium SY27</b> <b>Adjuvant treatment of melanoma</b>	<b>Symposium SY28</b> <b>Sentinel node biopsy: techniques and future perspectives</b>	<b>Satellite Symposium SAT08</b> <b>Further Sponsor</b> <i>(see page 39)</i>	<b>Symposium SY29</b> <b>Management of metastatic ocular melanoma</b>	<b>Symposium SY30</b> <b>Management of brain metastasis</b>
<b>10:30–10:33</b> <b>Introduction</b> Erika Richtig, Graz, Austria	<b>10:30–10:33</b> <b>Introduction</b> Alberto Wainstein, Belo Horizonte, Brazil		<b>10:30–10:33</b> <b>Introduction</b> Bastian Schilling, Wuerzburg, Germany	<b>10:30–10:33</b> <b>Introduction</b> Michael Davies, Houston, USA
<b>10:33–10:48</b> <b>Adjuvant immunotherapy</b> Jeffrey Weber, New York, USA	<b>10:33–10:48</b> <b>Does the sentinel lymph node biopsy by itself have any therapeutic benefit?</b> Mark Faries, Los Angeles, USA		<b>10:33–10:48</b> <b>Which patients should be considered for hepatic local treatment and why?</b> Matthew Wheeler, Southampton, United Kingdom	<b>10:33–10:48</b> <b>Use of immunotherapy for melanoma brain metastases</b> Michael Postow, New York, USA
<b>10:48–11:03</b> <b>Adjuvant targeted therapy</b> Georgina Long, Sydney, Australia	<b>10:48–11:03</b> <b>What will be the gold standard technics to sentinel lymph node biopsy approach for the next years?</b> Jeffrey Gershenwald, Houston, USA		<b>10:48–11:03</b> <b>Should immune checkpoint inhibitors be used in metastatic OM?</b> Bastian Schilling, Wuerzburg, Germany	<b>10:48–11:03</b> <b>Use of targeted therapy and combinatorial strategies for brain metastases</b> Friedegund Meier, Dresden, Germany
<b>11:03–11:18</b> <b>Who needs adjuvant treatment when melanoma can be cured by neo-adjuvant or palliative treatments?</b> Christian Blank, Amsterdam, The Netherlands	<b>11:03–11:18</b> <b>Which molecular, immunological or mulitpanel biomarkers are useful in clinical practice?</b> Daniella Massi, Florence, Italy		<b>11:03–11:18</b> <b>The role of ImmTacs in metastatic OM</b> Paul Nathan, London, United Kingdom	<b>11:03–11:18</b> <b>New insights into the unique features and pathogenesis of brain metastases</b> Michael Davies, Houston, USA
<b>11:18–11:30</b> <b>Discussion</b> Georgina Long, Sydney, Australia Erika Richtig, Graz, Austria	<b>11:18–11:30</b> <b>Discussion</b> Alexander van Akkooi, Amsterdam, The Netherlands Alberto Wainstein, Belo Horizonte, Brazil		<b>11:18–11:30</b> <b>Summary</b> Paul Nathan, London, United Kingdom	<b>11:18–11:30</b> <b>Summary</b> Friedegund Meier, Dresden, Germany
<b>11:30–11:45 Break – Please visit the virtual industrial exhibition and e-poster exhibition.</b>				

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
<div>11:45–12:45</div> <div>Satellite Symposium SAT09</div> <div>Platinum Sponsor</div> <div>(see page 39)</div> <div></div>				
12:45–13:00 Break – Please visit the virtual industrial exhibition and e-poster exhibition.				



FRIDAY, APRIL 16

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
13:00–14:30				
Keynote Lecture KEY02 Fundamental questions in dermatology-oncology				
13:00–13:01 Introduction Caroline Robert, Paris, France				
13:01–13:30 UV induced DNA-damage in skin cancer: mechanisms and significance Richard Marais, Manchester, United Kingdom				
13:30–13:31 Introduction Zeljko Mijuskovic, Belgrade, Serbia				
13:31–14:00 Cure of metastatic melanoma on the horizon? Georgina Long, Sydney, Australia				
14:00–14:01 Introduction Elisabeth Livingstone, Essen, Germany				
14:01–14:30 Covid and cancer Olivier Michielin, Lausanne, Switzerland				
14:30–14:45 Break – Please visit the virtual industrial exhibition and e-poster exhibition.				

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
<div>14:45–15:45</div> <div>Satellite Symposium SAT10</div> <div>Platinum Sponsor</div> <div>(see page 40)</div> <div></div>				
<div>15:45–16:00 Break – Please visit the virtual industrial exhibition and e-poster exhibition.</div>				



FRIDAY, APRIL 16

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
16:00–17:00	16:00–17:00	16:00–17:00	16:00–17:00	16:00–17:00
<b>Symposium SY31</b> Immune checkpoint inhibition for non-melanoma skin cancer	<b>Symposium SY32</b> Regulation of drug access across the world	<b>Satellite Symposium SAT11</b> Further Sponsor <i>(see page 40)</i>	<b>Symposium SY33</b> Immune checkpoint inhibition in immunocompromised patients	<b>Symposium SY34</b> New devices for skin cancer diagnostics
<b>16:00–16:03</b> Introduction Ralf Gutzmer, Hanover, Germany	<b>16:00–16:03</b> Introduction Gabriela Cinat, Buenos Aires, Argentina		<b>16:00–16:03</b> Introduction Eggert Stockfleth, Bochum, Germany	<b>16:00–16:03</b> Introduction Allan C. Halpern, New York, USA
<b>16:03–16:18</b> Merkel cell carcinoma Paul Nghiem, Seattle, USA	<b>16:03–16:18</b> Existing gaps in drug access in Europe and current solutions Lidija Kandolf-Sekulovic, Belgrade, Serbia		<b>16:03–16:18</b> Anti-PD-1/PD-L1 immunotherapy in transplant patients with advanced non melanoma skin cancer Céleste Lebbé, Paris, France	<b>16:03–16:18</b> Total body photography (3D/2D) and artificial intelligence Allan C. Halpern, New York, USA
<b>16:18–16:33</b> Basal cell carcinoma Ralf Gutzmer, Hanover, Germany	<b>16:18–16:33</b> Regulation of drug access, current obstacles and successful schemes in USA Sanjiv Agarwala, Philadelphia, USA		<b>16:18–16:33</b> How to manage anti-PD-1/anti-CTLA-4 immunotherapy in transplant patients with metastatic melanoma Brigitte Dreno, Nantes, France	<b>16:18–16:33</b> In vivo confocal reflectance microscopy and tomography Giovanni Pellacani, Rome, Italy
<b>16:33–16:48</b> Squamous cell carcinoma Michael Migden, Houston, USA	<b>16:33–16:48</b> Drug access schemes in LATAM countries Gabriela Cinat, Buenos Aires, Argentina		<b>16:33–16:48</b> New treatment options in the prevention of skin tumors in organ transplant recipients Eggert Stockfleth, Bochum, Germany	<b>16:33–16:48</b> In vivo LC-OCT and ex-vivo confocal microscopy for fast skin cancer histopathology Josep Malvehy, Barcelona, Spain
<b>16:48–17:00</b> Discussion Ralf Gutzmer, Hanover, Germany Christoph Höller, Vienna, Austria	<b>16:48–17:00</b> Discussion Gabriela Cinat, Buenos Aires, Argentina Lidija Kandolf-Sekulovic, Belgrade, Serbia		<b>16:48–17:00</b> Summary Brigitte Dreno, Nantes, France	<b>16:48–17:00</b> Summary Josep Malvehy, Barcelona, Spain
17:00–17:15 Break – Please visit the virtual industrial exhibition and e-poster exhibition.				

FRIDAY, APRIL 16

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
17:15–18:15	17:15–18:15	17:15–18:00	17:15–18:15	17:15–18:15
<b>Symposium SY35</b> <b>Highlights from AACR</b>	<b>Symposium SY36</b> <b>Melanocytic nevi: risks and management</b>	<b>Satellite Symposium SAT12</b> <b>Further Sponsor</b> <i>(see page 41)</i>	<b>Symposium SY37</b> <b>Promising agents for PD1-refractory patients in skin cancer</b>	<b>Symposium SY38</b> <b>Triplets for advanced metastatic melanoma: still hope for the future?</b>
<b>17:15–17:18</b> <b>Introduction</b> Martin McMahon, Salt Lake City, USA	<b>17:15–17:18</b> <b>Introduction</b> Jean Jacques Grob, Marseille, France		<b>17:15–17:18</b> <b>Introduction</b> Erwin Schultz, Nuremberg, Germany	<b>17:15–17:18</b> <b>Introduction</b> Axel Hauschild, Kiel, Germany
<b>17:18–17:40</b> <b>Update of AACR 2021 – Part I</b> Michael Postow, New York, USA	<b>17:18–17:33</b> <b>Congenital nevi: risks and management</b> Enzo Errichetti, Udine, Italy		<b>17:18–17:33</b> <b>RP1, RP2 and RP3: a new oncolytic immunotherapy platform</b> Robert Coffin, Woburn, USA	<b>17:18–17:33</b> <b>Are atezolizumab and spartalizumab as good as pembrolizumab and nivolumab? A cross comparison.</b> Hussein Tawbi, Houston, USA
<b>17:40–18:03</b> <b>Update of AACR 2021 – Part II</b> Helen Gogas, Athens, Greece	<b>17:33–17:48</b> <b>The atypical nevus/dysplastic conundrum</b> Ashfaq Marghoob, New York, USA		<b>17:33–17:48</b> <b>CMP-001, a CpG-A TLR9 agonist packaged in a virus-like particle</b> Art Krieg, Cambridge, USA	<b>17:33–17:48</b> <b>Comparison of clinical trial data on triplets</b> Paolo Ascierto, Naples, Italy
<b>Discussion</b> <b>18:03–18:15</b> Stephan Grabbe, Mainz, Germany Martin McMahon, Salt Lake City, USA	<b>17:48–18:03</b> <b>Nail and acral nevi: risks and management</b> Alex Chamberlain, Melbourne, Australia		<b>17:48–18:03</b> <b>FixVac (BNT-111): an new melanoma vaccine</b> Patrick Brück, Mainz, Germany	<b>17:48–18:03</b> <b>First experience with triplets in Switzerland</b> Reinhard Dummer, Zurich, Switzerland
	<b>18:03–18:15</b> <b>Discussion</b> Jean Jacques Grob, Marseille, France Jason Rivers, Vancouver, Canada		<b>18:03–18:15</b> <b>Summary</b> Stephan Grabbe, Mainz, Germany	<b>18:03–18:15</b> <b>Summary</b> Paolo Ascierto, Naples, Italy

Scientific Programme

SATURDAY, APRIL 17

SCIENTIFIC PROGRAMME

	LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C	
09:00	09:00–10:00 Symposium SY39 Primary prevention of skin cancer	09:00–10:15 Symposium SY40 Management of lentigo maligna melanomas		09:00–10:00 Symposium SY42 Management of rare skin cancers	09:00–10:00 Symposium SY43 Management of adverse events in immuno-oncology	09:00
10:00	10:15–11:15 Keynote Lecture KEY03 Diagnostics		09:45–10:05 Satellite Symposium SAT13 Further Sponsor (see page 41)			10:00
11:00						11:00
12:00	11:30–12:30 Symposium SY44 Interdisciplinary skin cancer centers: how they dealt with the Corona pandemic in different countries	11:30–12:30 Symposium SY45 Melanoma and Aging	11:30–12:30 Satellite Symposium SAT14 Further Sponsor (see page 41)	11:30–12:30 Symposium SY47 How to train young doctors in cutaneous oncology?	11:30–12:30 Symposium SY48 Electrochemotherapy in dermato-oncology	12:00
13:00	12:45–13:45 Symposium SY49 Evidence-based skin cancer guidelines	12:45–13:45 Symposium SY50 Artificial intelligence in dermato-oncology	12:45–13:45 Symposium SY51 Management of adverse events in targeted therapies	12:45–13:45 Symposium SY52 Is it as simple as making a cold tumor hot?	12:45–13:45 Symposium SY53 Management of melanoma in pregnancy	13:00
14:00	14:00–15:30 Symposium SY54 Controversies in melanoma	14:00–15:30 Symposium SY55 Actinic keratosis: recent treatment developments		14:00–15:30 Symposium SY56 Dermoscopy 2: Dermoscopy in melanoma management	14:00–15:30 Symposium SY57 Melanoma pathology – genomics and morphology	14:00
15:00			14:30–15:30 Satellite Symposium SAT15 Further Sponsor (see page 42)			15:00
16:00	15:45–17:15 Symposium SY58 Immunotherapies beyond checkpoint inhibition	15:45–17:15 Symposium SY59 Surgery of metastatic melanoma		15:45–17:15 Symposium SY61 Dermoscopy 3: Difficult clinical scenarios	15:45–17:15 Symposium SY62 Genetic susceptibility of melanoma and cancer syndromes	16:00
17:00			16:15–17:15 Satellite Symposium SAT16 Bronze Sponsor (see page 42)			17:00
18:00	17:15–17:25 Farewell and Poster Award					18:00



## SATURDAY, APRIL 17

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
09:00–10:00	09:00–10:15	09:45–10:05	09:00–10:00	09:00–10:00
<b>Symposium SY39</b> <b>Primary prevention of skin cancer</b>	<b>Symposium SY40</b> <b>Management of lentigo maligna melanomas</b>	<b>Satellite Symposium SAT13</b> <b>Further Sponsor</b> <i>(see page 41)</i>	<b>Symposium SY42</b> <b>Management of rare skin cancers</b>	<b>Symposium SY43</b> <b>Management of adverse events in immuno-oncology</b>
<b>09:00–09:03</b> <b>Introduction</b> Hans Peter Soyer, Brisbane, Australia	<b>09:00–09:03</b> <b>Introduction</b> Joseph Alcalay, Tel Aviv, Israel		<b>09:00–09:03</b> <b>Introduction</b> Maria Concetta Fargnoli, L'Aquila, Italy	<b>09:00–09:03</b> <b>Introduction</b> Gabriela Cinat, Buenos Aires, Argentina
<b>09:03–09:18</b> <b>Primary melanoma prevention in Australia: an update</b> David Whiteman, Brisbane, Australia	<b>09:03–09:18</b> <b>Diagnosis of lentigo maligna with handheld reflectance confocal microscopy: opportunity and pitfalls</b> Alon Scope, Tel Aviv, Israel		<b>09:03–09:18</b> <b>Merkel cell carcinoma: what has changed in its management recently?</b> Jürgen Becker, Essen, Germany	<b>09:03–09:18</b> <b>Serious and rare systemic adverse events: experience from an international registry</b> Lucie Heinzerling, Munich, Germany
<b>09:18–09:33</b> <b>The sunscreen and vitamin D debate: where are we in 2021?</b> Dagmar Whitaker, Cape Town, South Africa	<b>09:18–09:33</b> <b>Staged excision techniques for lentigo maligna: an alternative to Mohs surgery?</b> Ricardo Vieira, Coimbra, Portugal		<b>09:18–09:33</b> <b>Dermatofibrosarcoma protuberans: what has changed in its management recently?</b> Philippe Saiag, Boulogne Billancourt, France	<b>09:18–09:33</b> <b>Management of colitis beyond corticosteroids</b> John Haanen, Amsterdam, The Netherlands
<b>09:33–09:48</b> <b>From primary to secondary prevention: a holistic concept</b> Hans Peter Soyer, Brisbane, Australia	<b>09:33–09:48</b> <b>Surgical margins in lentigo maligna: how much is safe?</b> Eduardo Nagore, Valencia, Spain		<b>09:33–09:48</b> <b>Skin adnexal carcinomas; what has changed in their management recently?</b> Thomas Jouary, Bordeaux, France	<b>09:33–09:48</b> <b>Biomarkers of immune-related adverse events in melanoma</b> Jessica Hassel, Heidelberg, Germany
<b>09:48–10:00</b> <b>Discussion</b> Hans Peter Soyer, Brisbane, Australia Dagmar Whitaker, Cape Town, South Africa	<b>09:48–10:03</b> <b>Treating lentigo melanoma with Mohs surgery – yes, we can</b> Joseph Alcalay, Tel Aviv, Israel		<b>09:48–10:00</b> <b>Summary</b> Philippe Saiag, Boulogne Billancourt, France	<b>09:48–10:00</b> <b>Summary</b> Carola Berking, Erlangen, Germany
	<b>10:03–10:15</b> <b>Discussion</b> Joseph Alcalay, Tel Aviv, Israel Ricardo Vieira, Coimbra, Portugal			
10:00–10:15 Break – Please visit the virtual industrial exhibition and e-poster exhibition.				

SATURDAY, APRIL 17

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
10:15–11:15				
Keynote Lecture KEY03 Diagnostics				
10:15–10:16 Introduction Paolo Ascierto, Naples, Italy				
10:16–10:45 Why dermoscopy? Giuseppe Argenziano, Naples, Italy				
10:45–10:46 Introduction Ketty Peris, Rome, Italy				
10:46–11:15 From ugly duckling to artificial intelligence Jean Jacques Grob, Marseille, France				

SATURDAY, APRIL 17


LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
11:15–11:30 Break – Please visit the virtual industrial exhibition and e-poster exhibition.				
11:30–12:30	11:30–12:30	11:30–12:30	11:30–12:30	11:30–12:30
Symposium SY44 Interdisciplinary skin cancer centers: how they dealt with the Corona pandemic in different countries	Symposium SY45 Melanoma and aging	Satellite Symposium SAT14 Further Sponsor (see page 41)	Symposium SY47 How to train young doctors in cutaneous oncology ...	Symposium SY48 Electrochemotherapy in dermato-oncology
11:30–11:33 Introduction Caroline Robert, Paris, France	11:30–11:33 Introduction Marisol Soengas, Madrid, Spain		11:30–11:33 Introduction Van Anh Nguyen, Innsbruck, Austria	11:30–11:33 Introduction Piotr Rutkowski, Warsaw, Poland
11:33–11:48 Gustave Roussy Cancer Center in Paris Caroline Robert, Paris, France	11:33–11:48 How age impacts on my treatment decisions in high risk and metastatic melanoma Reinhard Dummer, Zurich, Switzerland		11:33–11:48 ... in Sydney Alexander Menzies, Sydney, Australia	11:33–11:48 H&N mucosal cancers treated with ECT Marco Benazzo, Pavia, Italy
11:48–12:03 Melanoma Institute Australia in Sydney Richard Scolyer, Sydney, Australia	11:48–12:03 Age against the machine: the impact of aging on melanoma progression Ashani Weeraratna, Baltimore, USA		11:48–12:03 ... in Barcelona Josep Malvehy, Barcelona, Spain	11:48–12:03 Visceral approach with ECT Attila Kovacs, Bonn, Germany
12:03–12:18 Moffitt Cancer Center in Tampa Vernon Sondak, Tampa, USA	12:03–12:18 Melanoma intratumor heterogeneity, growth and metastasis Jean-Christophe Marine, Leuven, Belgium		12:03–12:18 ... in Heidelberg Jessica Hassel, Heidelberg, Germany	12:03–12:18 ECT in combination with ICP inhibitors Judit Oláh, Szeged, Hungary
12:18–12:30 Discussion Caroline Robert, Paris, France Richard Scolyer, Sydney, Australia Vernon Sondak, Tampa, USA	12:18–12:30 Discussion Grant McArthur, Melbourne, Australia Marisol Soengas, Madrid, Spain		12:18–12:30 Summary Jessica Hassel, Heidelberg, Germany	12:18–12:30 Summary Alessandro Testori, Milan, Italy
12:30–12:45 Break – Please visit the virtual industrial exhibition and e-poster exhibition.				




SATURDAY, APRIL 17

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
12:45–13:45	12:45–13:45	12:45–13:45	12:45–13:45	12:45–13:45
<b>Symposium SY49</b> <b>Evidence-based skin cancer guidelines</b>	<b>Symposium SY50</b> <b>Artificial intelligence in dermato-oncology</b>	<b>Symposium SY51</b> <b>Management of adverse events in targeted therapies</b>	<b>Symposium SY52</b> <b>Is it as simple as making a cold tumor hot?</b>	<b>Symposium SY53</b> <b>Management of melanoma in pregnancy</b>
<b>12:45–12:48</b> <b>Introduction</b> Teresa Petrella, Toronto, Canada	<b>12:45–12:48</b> <b>Introduction</b> Harald Kittler, Vienna, Austria	<b>12:45–12:48</b> <b>Introduction</b> Katharina Kähler, Kiel, Germany	<b>12:45–12:48</b> <b>Introduction</b> John Haanen, Amsterdam, The Netherlands	<b>12:45–12:48</b> <b>Introduction</b> Selma Ugurel, Essen, Germany
<b>12:48–13:03</b> <b>Adjuvant and stage IV therapies in the Canadian Melanoma Guideline</b> Teresa Petrella, Toronto, Canada	<b>12:48–13:03</b> <b>State-of-the-art of artificial intelligence in dermatooncology</b> Josep Malvehy, Barcelona, Spain	<b>12:48–13:03</b> <b>Side effects associated with targeted therapies</b> Van Anh Nguyen, Innsbruck, Austria	<b>12:48–13:03</b> <b>Ex vivo tumor fragment platform to investigate cold and hot tumors</b> Daniela Thommen, Amsterdam, The Netherlands	<b>12:48–13:03</b> <b>Survey of management practices across Europe</b> Simone Ribero, Turin, Italy
<b>13:03–13:18</b> <b>Adjuvant and stage IV therapies in the German Melanoma Guideline</b> Thomas Eigentler, Tuebingen, Germany	<b>13:03–13:18</b> <b>Limitations and pitfalls of artificial intelligence in dermatooncology</b> Holger Hänßle, Heidelberg, Germany	<b>13:03–13:18</b> <b>Managing patients on targeted therapies</b> Katharina Kähler, Kiel, Germany	<b>13:03–13:18</b> <b>The complexity of changing cold tumors</b> Stefani Spranger, Cambridge, USA	<b>13:03–13:18</b> <b>Oestrogen progesterone receptors in melanoma and nevi</b> Emi Dika, Bologna, Italy
<b>13:18–13:33</b> <b>Adjuvant and stage IV therapies in the US Melanoma Guideline</b> Jeffrey Weber, New York, USA	<b>13:18–13:33</b> <b>Human-computer collaboration for skin cancer diagnosis</b> Harald Kittler, Vienna, Austria	<b>13:18–13:33</b> <b>Challenging cases</b> Jakob Schachter, Tel Aviv, Israel	<b>13:18–13:33</b> <b>Improving susceptibility to immunotherapy using intralesional therapies</b> Robert Andtbacka, Edison, USA	<b>13:18–13:33</b> <b>Does pregnancy affect melanoma prognosis?</b> Catarina Longo, Reggio, Italy
<b>13:33–13:45</b> <b>Discussion</b> Thomas Eigentler, Tuebingen, Germany Teresa Petrella, Toronto, Canada	<b>13:33–13:45</b> <b>Discussion</b> Holger Hänßle, Heidelberg, Germany Harald Kittler, Vienna, Austria	<b>13:33–13:45</b> <b>Summary</b> Van Anh Nguyen, Innsbruck, Austria	<b>13:33–13:45</b> <b>Summary</b> Stephan Grabbe, Mainz, Germany	<b>13:33–13:45</b> <b>Summary</b> Veronique Bataille, London, United Kingdom
<b>13:45–14:00 Break – Please visit the virtual industrial exhibition and e-poster exhibition.</b>				

SATURDAY, APRIL 17

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
14:00–15:30	14:00–15:30	14:30–15:30	14:00–15:30	14:00–15:30
Symposium SY54 Controversies in melanoma	Symposium SY55 Actinic keratosis: recent treatment developments	Satellite Symposium SAT15 Further Sponsor (see page 42)	Symposium SY56 Dermoscopy 2: Dermoscopy in melanoma management	Symposium SY57 Melanoma pathology – genomics and morphology
14:00–14:03 Introduction Mario Santinami, Milan, Italy	14:00–14:03 Introduction Maria Concetta Fargnoli, L’Aquila, Italy		14:00–14:03 Introduction Iris Zalaudek, Trieste, Italy	14:00–14:03 Introduction Boris Bastian, San Francisco, USA
Is surgery still standard of care in stage III/IV?	14:03–14:18 Why treat actinic keratosis Nicole Kelleners–Smeets, Maastricht, The Netherlands		14:03–14:18 Does dermoscopy save lives? Harald Kittler, Vienna, Austria	14:03–14:18 Spitz tumors, towards a unified definition Iwei Yeh, San Francisco, USA
14:03–14:18 Yes: Merrick Ross, Houston, USA	14:18–14:33 Lesion directed treatment: what’s new Rolf–Markus Szeimies, Recklinghausen, Germany		14:18–14:33 Clinical clues for melanoma diagnosis Iris Zalaudek, Trieste, Italy	14:18–14:33 Highly multiplex immunofluorescence and AI image analysis for personalised immunotherapy selection James Wilmott, Sydney, Australia
14:18–14:33 No: Alexander Eggermont, Utrecht, The Netherlands	14:33–14:48 Field directed treatment: what’s new Maria Concetta Fargnoli, L’Aquila, Italy		14:33–14:48 Role of dermoscopy before and after treatment of melanoma and non–melanoma skin cancers Zoe Apalla, Thessaloniki, Greece	14:33–14:48 How do you recognise BAP1 inactivated melanocytic tumors and what is their significance? Arnaud de la Fourchadière, Lyon, France
14:33–14:45 Discussion Axel Hauschild, Kiel, Germany Mario Santinami, Milan, Italy	14:48–15:03 Treatment of the immunosuppressed patient Catherine Harwood, London, United Kingdom		14:48–15:03 e-Health in the oncologic patients care Josep Malvehy, Barcelona, Spain	14:48–15:03 UV-radiation and melanocytic neoplasia Amaya Viros, Manchester, United Kingdom
14:45–14:48 Introduction Axel Hauschild, Kiel, Germany	15:03–15:18 Chemoprevention of actinic keratosis / nonmelanoma skin cancers Diona Damian, Sydney, Australia		15:03–15:18 Dermoscopy of nested melanoma Claudio Conforti, Trieste, Italy	15:03–15:18 Similarities and differences between blue nevi and related tumors and uveal melanomas – are they twins or distant relatives? Klaus Griewank, Mainz, Germany
Is whole brain irradiation still standard of care?	15:18–15:30 Discussion Axel Hauschild, Kiel, Germany Mario Santinami, Milan, Italy		15:18–15:30 Summary Carlos Barcaui, Rio de Janeiro, Brazil	15:18–15:30 Summary Richard Scolyer, Sydney, Australia
14:48–15:03 Yes: Lars Bastholt, Odense, Denmark				
15:03–15:18 No: Bernardo Rapoport, Johannesburg, South Africa				
15:18–15:30 Discussion Axel Hauschild, Kiel, Germany Mario Santinami, Milan, Italy				
15:30–15:45 Break – Please visit the virtual industrial exhibition and e-poster exhibition.				

SATURDAY, APRIL 17

LIVE STREAM 1	LIVE STREAM 2	HALL A	HALL B	HALL C
15:45–17:15	15:45–17:15	16:15–17:15	15:45–17:15	15:45–17:15
<b>Symposium SY58</b> <b>Immunotherapies beyond checkpoint inhibition</b>	<b>Symposium SY59</b> <b>Surgery of metastatic melanoma</b>	<b>Satellite Symposium SAT16</b> <b>Bronze Sponsor</b> <i>(see page 42)</i>	<b>Symposium SY61</b> <b>Dermoscopy 3: Difficult clinical scenarios</b>	<b>Symposium SY62</b> <b>Genetic susceptibility of melanoma and cancer syndromes</b>
<b>15:45–15:48</b> <b>Introduction</b> Paul Lorigan, Manchester, United Kingdom	<b>15:45–15:48</b> <b>Introduction</b> Piotr Rutkowski, Warsaw, Poland		<b>15:45–15:48</b> <b>Introduction</b> Aimilios Lallas, Thessaloniki, Greece	<b>15:45–15:48</b> <b>Introduction</b> Maria Teresa Landi, Bethesda, USA
<b>15:48–16:03</b> <b>IL–2 like drugs including NKTR-214 and ALKS 4230</b> Adi Diab, Houston, USA	<b>15:48–16:03</b> <b>The current strategies in surgical therapy of stage III metastases</b> Piotr Rutkowski, Warsaw, Poland		<b>15:48–16:03</b> <b>Face: dermoscopy hints</b> Caterina Longo, Reggio Emilia, Italy	<b>15:48–16:03</b> <b>Genetic susceptibility in familial melanomas, with emphasis on families from Mediterranean countries</b> Cristina Pellegrini, L'Aquila, Italy
<b>16:03–16:18</b> <b>Adoptive cell therapy with TIL and other effector cells</b> Inge-Marie Svane, Copenhagen, Denmark	<b>16:03–16:18</b> <b>Locoregional approach in in-transit metastases</b> Dirk Gruenhagen, Rotterdam, The Netherlands		<b>16:03–16:18</b> <b>Acral and mucosal areas: what we should know</b> Aimilios Lallas, Thessaloniki, Greece	<b>16:03–16:18</b> <b>Novel high penetrant susceptibility genes from pooled analyses of worldwide melanoma-prone families</b> Nicholas Hayward, Brisbane, Australia
<b>16:18–16:33</b> <b>Cytokines and growth factors including TGF-beta</b> Ignacio Melero, Pamplona, Spain	<b>16:18–16:33</b> <b>The impact of systemic perioperative treatment on surgery in stage III melanoma</b> Mario Mandalá, Bergamo, Italy		<b>16:18–16:33</b> <b>Nail: the issue of pigmented band</b> Cristina Carrera, Barcelona, Spain	<b>16:18–16:33</b> <b>Non-coding genetic changes in 9p21-linked melanoma-prone families</b> Antonia Pritchard, Inverness, United Kingdom
<b>16:33–16:48</b> <b>Epigenetic modifiers</b> Ryan J. Sullivan, Boston, USA	<b>16:33–16:48</b> <b>Surgery of distant metastases as elective treatment in selected cases or in combination with medical therapy: when and what</b> Merrick Ross, Houston, USA		<b>16:33–16:48</b> <b>Practical tips for an accurate digital monitoring</b> John Paoli, Gothenburg, Sweden	<b>16:33–16:48</b> <b>Genetic susceptibility loci and related pathways from genome-wide association studies of melanoma and other traits</b> Maria Teresa Landi, Bethesda, USA
<b>16:48–17:03</b> <b>New approaches with neoantigen vaccines/ T-cell therapies</b> Samra Turajlic, London, United Kingdom	<b>16:48–17:03</b> <b>Case presentation and discussion</b> Alexander van Akkooi, Amsterdam, The Netherlands		<b>16:48–17:03</b> <b>Cases: the best and the worst</b> Philipp Tschandl, Vienna, Austria	<b>16:48–17:03</b> <b>Melanoma and other tumors in BAP1-related syndrome</b> Brigitte Bressac-de Paillerets, Paris, France
<b>17:03–17:15</b> <b>Discussion</b> Paul Lorigan, Manchester, United Kingdom Jeffrey Weber, New York, USA	<b>17:03–17:15</b> <b>Discussion</b> Piotr Rutkowski, Warsaw, Poland Mario Santinami, Milan, Italy		<b>17:03–17:15</b> <b>Summary</b> Caterina Longo, Reggio Emilia, Italy	<b>17:03–17:15</b> <b>Summary</b> Nicholas Hayward, Brisbane, Australia

**17:15–17:25 Farewell and Poster Award Ceremony**  
Paolo Ascierto, Naples, Italy  
Claus Garbe, Tuebingen, Germany  
Axel Hauschild, Kiel, Germany  
Ketty Peris, Rome, Italy  
Mario Santinami, Milan, Italy



THURSDAY, APRIL 15

09:30–10:30  
LIVE STREAM 2

SAT01 Gold Sponsor



Expanding Treatment Strategies for Patients with Melanoma and Nonmelanoma Skin Cancers

- 09:30–09:35 **Chair’s Welcome and Introduction**  
Paolo A. Ascierto, Naples, Italy
- 09:35–09:50 **Adjuvant Treatment of Melanoma: The Current State and Future Perspectives**  
Alexander C. J. van Akkooi, Amsterdam, The Netherlands
- 09:50–10:05 **Exploring the Current and Evolving Landscape in Advanced Melanoma**  
Axel Hauschild, Kiel, Germany
- 10:05–10:20 **Evolving Treatment Strategies in Advanced cSCC**  
Dirk Schadendorf, Essen, Germany
- 10:20–10:30 **Live Q&A / Panel Discussion**  
All Faculty
- Close**  
Paolo A. Ascierto, Naples, Italy

THURSDAY, APRIL 15

12:45–13:45  
LIVE STREAM 1

SAT02 Platinum Sponsor



Navigating Early-Stage Melanoma: Systemic Treatment Today and in the Future?

- 12:45–12:50 **Welcome and Introduction**  
Dirk Schadendorf, Essen, Germany
- 12:50–13:00 **Early-Stage Melanoma: Is There a Clinical Need?**  
Anna K. Winge-Main, Oslo, Norway
- 13:00–13:15 **How Are We Treating Early-Stage Patients Today and Why?**  
Dirk Schadendorf, Essen, Germany
- 13:15–13:30 **The Future for Early-Stage Melanoma: How, When, and Who to Treat?**  
Paul Lorigan, Manchester, United Kingdom
- 13:30–13:45 **Live Q&A**  
All Faculty

THURSDAY, APRIL 15

14:00–15:00  
LIVE STREAM 2

SAT03 Gold Sponsor



Pierre Fabre

**Perspectives on achieving optimal outcomes in advanced *BRAF*-mutant melanoma during challenging times**

14:00–14:05 **Welcome and introductions**  
Caroline Robert, Paris, France

14:05–14:15 **Beyond clinical data: What ‘optimal outcomes’ mean for patients with advanced melanoma**  
Caroline Robert, Paris, France

14:15–14:55 **Managing advanced *BRAF*-mutant melanoma during unprecedented circumstances**

- Patient perspective (*video*)
- Exchange of views: COVID-19 pandemic experience – an EU and US perspective (*live session*)  
Hussein A. Tawbi, Houston, US & Paolo Ascierto, Naples, Italy
- Key challenges in achieving optimal patient care (*panel discussion*)  
All faculty. Moderated by Axel Hauschild, Kiel, Germany
- Audience Q&A

14:55–15:00 **Closing Remarks**  
Axel Hauschild, Kiel, Germany

THURSDAY, APRIL 15

15:15–16:15  
HALL A

SAT04 Further Sponsor

NERACARE

**At what risk should adjuvant treatment of melanoma be considered? Does gene expression profiling (GEP) support us here?**

15:15–15:20 **Welcome**  
Axel Hauschild, Kiel, Germany; Vernon Sondak, Tampa, USA

15:20–15:30 **Finding the right threshold for risks and benefits of adjuvant treatment**  
Vernon Sondak, Tampa, USA

15:30–15:40 **Melagenix: a new GEP test for melanoma primaries**  
Claus Garbe, Tübingen, Germany

15:40–15:55 **Retrospective and prospective studies in stage II/III: evaluation of scores for treatment selection**  
Dirk Schadendorf, Essen, Germany

15:55–16:00 **GEP-based adjuvant treatment for stage IIA-C: the DeCOG trial**  
Axel Hauschild, Kiel, Germany

16:00–16:15 **Q&A with voting system**  
All faculty

THURSDAY, APRIL 15

16:30–17:30  
HALL A

SAT05 Further Sponsor



Advanced basal cell carcinoma: an exploration  
of clinical challenges and what the future could hold

- 16:30–16:33 **Welcome and introduction**  
Alexander Stratigos, Athens, Greece
- 16:33–16:45 **The challenges of managing aBCC: let’s discuss!**  
Alexander Stratigos, Athens, Greece  
Paolo Bossi, Milan, Italy  
Ralf Gutzmer, Hannover, Germany
- 16:43–16:58 **When hedgehog pathway inhibitors fail, what future strategies  
could offer hope for patients with aBCC?**  
Alexander Stratigos, Athens, Greece  
Paolo Bossi, Milan, Italy; Ralf Gutzmer, Hannover, Germany
- 16:58–17:18 **The clinical implications of systemic therapy for aBCC:  
what are your thoughts?**  
Alexander Stratigos, Athens, Greece  
Paolo Bossi, Milan, Italy  
Ralf Gutzmer, Hannover, Germany
- 17:18–17:30 **Audience Q&A**  
Alexander Stratigos, Athens, Greece  
Paolo Bossi, Milan, Italy  
Ralf Gutzmer, Hannover, Germany

*This activity is supported by an independent medical education grant  
from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.*

THURSDAY, APRIL 15

17:45–18:45  
LIVE STREAM 2

SAT05A Bronze Sponsor



FRIDAY, APRIL 16

FRIDAY, APRIL 16

08:00–09:00  
HALL A

SAT06 Further Sponsor



Refining the role of SLNB in melanoma

- 08:00–08:10 **Introduction**  
Tina Hieken, Rochester, USA
- 08:10–08:20 **Pathology perspective**  
Daniela Massi, Florence, Italy
- 08:20–08:30 **Dermatology perspective**  
Alexander Meves, Rochester, USA
- 08:30–08:40 **Surgical oncology perspective**  
Vernon Sondak, Tampa, USA
- 08:40–09:00 **Q&A panel**  
Alexander Eggermont, Utrecht, The Netherlands

09:15–10:15  
LIVE STREAM 2

SAT07 Bronze Sponsor



Insights on the basal cell carcinoma treatment paradigm:  
current standards of care and emerging approaches

- 09:15–09:20 **Opening remarks and introductions**  
Ralf Gutzmer, Hannover, Germany
- 09:20–09:30 **Identifying and treating high-risk BCC**  
Ralf Gutzmer, Hannover, Germany  
Nicole Basset-Seguín, Paris, France  
Omid Hamid, Los Angeles, USA
- 09:30–09:40 **Frontline systemic therapy for advanced BCC**  
Ralf Gutzmer, Hannover, Germany  
Nicole Basset-Seguín, Paris, France  
Omid Hamid, Los Angeles, USA
- 09:40–10:00 **Immunotherapy as an emerging option for advanced BCC**  
Ralf Gutzmer, Hannover, Germany  
Nicole Basset-Seguín, Paris, France  
Omid Hamid, Los Angeles, USA
- 10:00–10:05 **Closing remarks**  
Ralf Gutzmer, Hannover, Germany  
Nicole Basset-Seguín, Paris, France  
Omid Hamid, Los Angeles, USA
- 10:05–10:15 **Audience questions**  
Ralf Gutzmer, Hannover, Germany  
Nicole Basset-Seguín, Paris, France  
Omid Hamid, Los Angeles, USA

FRIDAY, APRIL 16

10:30–11:30  
HALL A**SAT08 Further Sponsor****Odomzo (sonidegib) in laBCC: what we have learned from European clinical practice**

- 10:30–10:35 **Welcome and introduction**  
Paolo Ascierto, Naples, Italy
- 10:35–10:48 **Interactive clinical case**  
Nicole Basset-Seguin, Paris, France
- 10:48–11:01 **Interactive clinical case**  
Ralf Gutzmer, Hannover, Germany
- 11:01–11:14 **Interactive clinical case**  
Paolo Bossi, Brescia, Italy
- 11:14–11:26 **Discussion and Q&A**  
All
- 11:26–11:30 **Conclusion**  
Paolo Ascierto, Naples, Italy

FRIDAY, APRIL 16

11:45–12:45  
LIVE STREAM 1**SAT09 Platinum Sponsor****Optimizing patient care in 2021: targeted therapy for BRAF-mutant melanoma**

- 11:45–11:50 **Welcome and introduction**  
Reinhard Dummer, Zurich, Switzerland
- 11:50–12:05 **Quality of life – a priority in patient care**  
Caroline Robert, Paris, France
- 12:05–12:20 **Safety considerations in the current era of melanoma management**  
Reinhard Dummer, Zurich, Switzerland
- 12:20–12:35 **The rise of digital health in melanoma patient care**  
Monika Janda, Queensland, Australia
- 12:35–12:45 **Audience Q&A, summary and close**  
All speakers

## FRIDAY, APRIL 16

14:45–15:45  
LIVE STREAM 1

SAT10 Platinum Sponsor

SANOFI GENZYME **A clinical dialogue on the expanding role of immunotherapy in advanced non-melanoma skin cancer**

- 14:45–14:50 **Welcome and introduction**  
Axel Hauschild, Kiel, Germany
- 14:50–15:00 **Management considerations for patients with advanced non-melanoma skin cancer: implications for practice**  
Axel Hauschild, Kiel, Germany
- 15:00–15:15 **The role of multi-disciplinary management in high-risk cutaneous squamous cell carcinoma (CSCC): a surgeon's perspective**  
Neil D. Gross, Houston, USA
- 15:15–15:30 **Immunotherapy as an emerging treatment approach for advanced basal cell carcinoma (BCC)**  
Ketty Peris, Rome, Italy
- 15:30–15:45 **Ask the faculty and concluding remarks**  
All faculty

## FRIDAY, APRIL 16

16:00–17:00  
HALL A

SAT11 Further Sponsor

 KYOWA KIRIN**Mogamulizumab for the treatment of mycosis fungoides and Sézary syndrome: the importance of assessing blood involvement to optimise patient management and outcomes**

- 16:00–16:05 **Welcome and introduction**  
Pietro Quaglino, Turin, Italy
- 16:05–16:20 **CCR4 as a target in MF and SS**  
Jan P. Nicolay, Mannheim, Germany
- 16:20–16:35 **The importance of blood involvement in MF and SS**  
Pietro Quaglino, Turin, Italy
- 16:35–16:45 **Real-world experience of Mogamulizumab case studies**  
Pietro Quaglino, Turin, Italy  
Jan P. Nicolay, Mannheim, Germany
- 16:45–16:55 **Audience Q&A**  
Pietro Quaglino, Turin, Italy  
Jan P. Nicolay, Mannheim, Germany
- 16:55–17:00 **Summary and close**  
Jan P. Nicolay, Mannheim, Germany



## FRIDAY, APRIL 16

17:15–18:00  
HALL A

## SAT12 Further Sponsor


**Smart digital health for skin cancer care:  
a new evolving paradigm shift?**

17:15–17:30 **Impact of Covid-19 pandemic in skin cancer care  
clinical management: how digital technology could help?**  
Josep Malvehy, Barcelona, Spain

17:30–17:45 **Implementation of clinical digital health solutions  
in dermatology: evaluation of treatment options in AK**  
Giovanni Pellacani, Rome, Italy

17:45–18:00 **Q&A discussion**  
Josep Malvehy, Barcelona, Spain  
Giovanni Pellacani, Rome, Italy

## SATURDAY, APRIL 17

09:45–10:05  
HALL A

## SAT13 Further Sponsor

11:30–12:30  
HALL A

## SAT14 Further Sponsor


**ACT IN CONTROL: Prevention, treatment and follow-up of actinic  
keratosis and NMSC in times of pandemic**

11:30–11:45 **Actinic keratosis diagnosis and treatment: what's new**  
Eggert Stockfleth, Bochum, Germany

11:45–12:00 **Can you feel it? Discover Eucerin's 1st medical device ACTINIC  
CONTROLMD SPF 100 for prevention and adjunctive treatment of  
actinic keratosis and NMSC**  
Julia Gallinger, Hamburg, Germany

12:00–12:15 **AK on the RADAR: risk management – active surveillance –  
digital follow-up – adherence to prevention – rapidity and  
simplification**  
Giuseppe Argenziano, Naples, Italy

12:15–12:30 **Discussion / Q&A**  
All faculty

SATURDAY, APRIL 17

14:30–15:30  
HALL A

SAT15 Further Sponsor



Diagnostic and prognostic testing in melanoma and cutaneous squamous cell carcinoma

16:15–17:15  
HALL A

SAT16 Bronze Sponsor



Plasmid DNA-based intratumoral immunotherapies delivered via electroporation: activating the immune system to achieve meaningful tumor responses without systemic toxicities


16:15–16:18 Introduction  
Christopher G. Twitty, Pennington, USA

16:18–16:28 OncoSec’s KEYNOTE-695 interim data  
Paolo Ascierto, Naples, Italy

16:28–16:48 OncoSec’s next generation therapies: amplification of the CXR3/CXCL9 axis via intratumoral electroporation of CXCL9 synergizes with IL-12 therapy (TAVO) to elicit robust anti-tumor immunity  
Christopher G. Twitty, Pennington, USA

16:48–17:15 Live Q&A  
Christopher G. Twitty, Pennington, USA; Paolo Ascierto, Naples, Italy

©2020 3Gen, Inc. All rights reserved. DermLite and 3Gen are registered trademarks of 3Gen, Inc. See dermlite.com/patents for more details.



dermLite®

The Only Patented Polarization System that Gives you Superpowers.  
DermLite hooks up to virtually any smartphone or tablet and any third-party app for mole monitoring, analysis or teledermoscopy.

Poster Awards

The research award is kindly supported by



The scientific award is kindly supported by



The case award is kindly supported by



## Sponsors

### PLATINUM SPONSORS

 Bristol Myers Squibb™

 NOVARTIS

SANOFI GENZYME 

### GOLD SPONSORS

 MSD

 Pierre Fabre

### BRONZE SPONSOR

REGENERON | SANOFI GENZYME 

 oncosec™  
IMMUNOTHERAPIES

 Roche

### SPONSORS AND EXHIBITORS

 4SC

 almirall  
feel the science

 AMGEN®

 BIONTECH

 CASTLE  
BIOSCIENCES

 CHECKMATE  
PHARMACEUTICALS

 dermLite®

 Eucerin®

 HEINE

 HERUS®

 ICEA®  
CLINICAL BIOPHYSICS

IMMUNOCORE

 IOVANCE  
BIOTHERAPEUTICS

 YOWA KIRIN

 medac

 NEKTAR®

 NERACARE

 PeerVoice

 Philogen  
innovating targeting

 Replimune®


 SkylineDx

 SUN  
PHARMA



# Transforming patients' lives through science™

We are in the business of breakthroughs—the kind that transform patients' lives. Dedicated to our mission of discovering, developing and delivering life-saving innovations that help patients prevail over serious diseases, we'll never give up our search for more hope, for more people, around the world.



We're proud to support the 10th World Congress  
of Melanoma & 17th EADO Congress 2021

Visit [bms.com](https://bms.com) to see how we're bringing a human touch to everything we do.



Our multiyear **When Cancer Grows Old™** initiative is intended to address the challenges of cancer and aging. We are collaborating with the global cancer community of advocates, healthcare providers and policymakers around the world to find solutions and create change so that aging patients with cancer have the best possible chance to grow old.

## OUR YEAR ONE COMMITMENT INCLUDES PLANS TO:



**LAUNCH A GLOBAL STUDY TO FURTHER  
DEFINE THE SPECIFIC POLICY GAPS**



**COLLABORATE WITH EXPERTS IN AGING, CANCER,  
POLICY, ADVOCACY, RESEARCH AND CARE TO FURTHER  
DEFINE THE UNIQUE CHALLENGES**



**ISSUE A GLOBAL CALL FOR ENTREPRENEURS AND  
DEVELOPERS TO INVENT SOLUTIONS TO HELP ADDRESS GAPS**



**COMMIT FUNDING TO ADVOCACY  
GROUPS TO SUPPORT THIS POPULATION**



# INSIGHTS ON THE BASAL CELL CARCINOMA TREATMENT PARADIGM:

## Current Standards of Care and Emerging Approaches

**FRIDAY, 16 APRIL 2021**

9:15 – 10:15 CEST

3:15 AM – 4:15 AM ET

12:15 AM – 1:15 AM PT



Melanoma  
World Society  
**MWS**

## VIRTUAL SYMPOSIUM LIVE STREAM 2

### INSIGHTS FROM INVESTIGATORS (AND A PATIENT)

During the 2021 World Congress of Melanoma in conjunction with EADO, please join our expert faculty for this interactive panel discussion. They will provide privileged insights into the evolving basal cell carcinoma (BCC) treatment paradigm.

To augment these insights, an experienced patient with advanced BCC will join the panel to share “teaching moments” from his treatment journey.

### EDUCATIONAL OBJECTIVES

*After completing this activity, the clinician should be better able to:*

- Distinguish between high- and low-risk BCC
- Apply the current standard of care for treating high-risk BCC
- Select appropriate front-line systemic therapy for advanced BCC
- Evaluate emerging efficacy and safety data for immunotherapy in advanced BCC, offering clinical trial enrollment where appropriate

### EXPERT FACULTY



**Prof. Ralf Gutzmer, MD (Chair)**  
Head, Skin Cancer Center Hannover  
Department of Dermatology  
Hannover Medical School  
Hannover, Germany



**Prof. Nicole Basset-Seguín, MD, PhD**  
Policlinique de dermatologie  
Hôpital Saint-Louis  
Université de Paris  
Paris, France



**Omid Hamid, MD**  
Chief of Research/Immuno-Oncology  
The Angeles Clinic & Research Institute  
Co-Director, Cutaneous Malignancy Program  
Cedars-Sinai CANCER  
Los Angeles, USA

### PROGRAM AGENDA

<b>Opening Remarks &amp; Introductions</b> Prof. Ralf Gutzmer, MD	9:15 - 9:20
<b>Identifying and Treating High-Risk BCC</b> All Faculty	9:20 - 9:30
<b>Frontline Systemic Therapy for Advanced BCC</b> All Faculty	9:30 - 9:40
<b>Immunotherapy as an Emerging Option for Advanced BCC</b> All Faculty	9:40 - 10:00
<b>Closing Remarks</b> Prof. Ralf Gutzmer, MD	10:00 - 10:05
<b>Audience Questions</b> All Faculty	10:05 - 10:15

### TARGET AUDIENCE

Oncology, dermatology, and dermato-oncology clinicians who manage patients with basal cell carcinoma (BCC).

### PROVIDER STATEMENT

This educational activity was independently developed by RMEI Medical Education, LLC in collaboration with Advancing Knowledge in Healthcare (AKH) Inc. All faculty and planner conflicts of interest were identified and resolved and AKH has reviewed the content and determined it to be fair, balanced, and without commercial bias.

### STATEMENT OF SUPPORT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

### FEE STATEMENT

There is no fee for this educational activity.

### QUESTIONS?

Please contact Stephanie Kielt at [skielt@rmei.com](mailto:skielt@rmei.com) if you have any questions.